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Abstract 
 
Educators often use online material to aid in student learning. After reviewing academic and 
corporate sources, the team determined the primary effects of the advances in genome 
sequencing technologies. Based on survey responses, it was determined that many people are not 
familiar with these effects. Consequently, the team developed a series of educational videos and 
supplemental assignments that provide an introduction to genome sequencing technologies, as 
well as their worldwide impacts on legislation, economy, forensics, health care, and biological 
research.  
  
5 
 
Table of Contents 
AUTHORSHIP .......................................................................................................................................... 2 
ACKNOWLEDGEMENTS ........................................................................................................................ 3 
ABSTRACT ................................................................................................................................................ 4 
TABLE OF TABLES ................................................................................................................................. 8 
TABLE OF FIGURES ............................................................................................................................... 9 
LIST OF ACRONYMS ............................................................................................................................ 10 
EXECUTIVE SUMMARY ....................................................................................................................... 12 
CHAPTER 1: INTRODUCTION .......................................................................................................... 15 
CHAPTER 2: BACKGROUND ON GENOME SEQUENCING TECHNOLOGIES ......................... 17 
2.1 The Sanger Method – 1
st
 Generation Genome Sequencing ............................................................................ 17 
2.2 Second Generation Sequencing Technologies ................................................................................................ 19 
2.2.1 Roche 454 System .......................................................................................................................................... 19 
2.2.2 Sequencing Systems by Illumina, Inc. ............................................................................................................ 21 
2.2.3 Applied Biosystems SOLiD System ................................................................................................................. 25 
2.3 Third Generation Sequencing Technologies ................................................................................................... 28 
2.3.1 Helicos BioSciences True Single Molecule Sequencing (tSMS) ...................................................................... 28 
2.3.2 Pacific Biosciences Single Molecule Real Time Sequencing (SMRT) .............................................................. 31 
2.4 Additional Sequencing Methods .................................................................................................................... 33 
2.4.1 Direct Sequencing via TEM by ZS Genetics .................................................................................................... 33 
2.4.2 Nanopore Sequencing .................................................................................................................................... 33 
2.4.3 Electronic Scanning Tunneling Microscopy (STM) ......................................................................................... 34 
2.4.4 NanoKnife Edge Probe Method by Revase .................................................................................................... 34 
2.4.5 Sequencing by Synthesis (SBS) by Intelligent Biosystems .............................................................................. 36 
2.4.6 DNA Nano-ball Method.................................................................................................................................. 36 
2.5 Computational Methods ................................................................................................................................ 37 
2.5.1 Computational Challenges Posed by New Genome Sequencing Technologies ............................................. 38 
2.5.2 Data Processing and Management ................................................................................................................ 38 
2.5.3 Analyzing Sequence Data ............................................................................................................................... 39 
2.6 Combining Sequencing Technologies ............................................................................................................. 41 
2.7 Projections ..................................................................................................................................................... 42 
6 
 
CHAPTER 3: IMPACTS AND APPLICATIONS OF GENOME SEQUENCING ............................ 44 
3.1 Economy ........................................................................................................................................................ 44 
3.2 Worldwide Legislation Regarding the Release of Genetic Information ........................................................... 48 
3.2.1 Implications of Genome Ownership, Privacy, and Disclosure ....................................................................... 48 
3.2.2 Legislation in the United States ..................................................................................................................... 50 
3.2.3 Legislation in Europe ...................................................................................................................................... 51 
3.2.4 Legislation in Australia ................................................................................................................................... 52 
3.2.5 Legislation in Japan ........................................................................................................................................ 53 
3.2.6 Legislation in China ........................................................................................................................................ 53 
3.2.7 Legislation in Developing Countries ............................................................................................................... 54 
3.2.8 Cultural and Religious Barriers ....................................................................................................................... 54 
3.3 Forensics ........................................................................................................................................................ 55 
3.4 Medicine ........................................................................................................................................................ 57 
3.4.1 Medical Diagnosis, Treatment, and Cancer Research .................................................................................... 57 
3.4.2 Personalized Drug Development ................................................................................................................... 58 
3.4.3 Disease Prevention and Vaccination .............................................................................................................. 62 
3.5 Advances in Genetic Research ........................................................................................................................ 62 
3.5.1 Mutation Discovery and Defining Variability Across Human Genomes ......................................................... 63 
3.5.2 Sequencing Clinical Isolates in Strain-to-Reference Comparisons ................................................................. 63 
3.5.3 Enabling Metagenomics ................................................................................................................................. 64 
3.5.4 Defining DNA–Protein Interactions and Regulatory Protein Binding............................................................. 64 
3.5.5 Exploring Chromatin Packaging and Noncoding RNAs................................................................................... 65 
3.6 Evolution ........................................................................................................................................................ 65 
3.7 Agriculture ..................................................................................................................................................... 67 
CHAPTER 4: SURVEYING WPI STUDENTS AND FACULTY ...................................................... 70 
4.1 Creating and Implementing the Student Survey ............................................................................................. 70 
4.2 Results and Discussion of the Student Survey ................................................................................................ 71 
4.2.1 Respondent Demographics ............................................................................................................................ 71 
4.2.2 Stated Familiarity and Interest Ratings on the Impacts of Genome Sequencing Technologies .................... 72 
4.2.3 Student Responses to the Changes Brought By Advances in Sequencing Technologies ............................... 75 
4.3 Creating and Implementing the Faculty Survey .............................................................................................. 79 
4.4 Results and Analysis of the Faculty Survey ..................................................................................................... 80 
CHAPTER 5: DEVELOPING EDUCATIONAL MATERIALS ......................................................... 82 
5.1 Creating the Preview Video and Obtaining Feedback ..................................................................................... 82 
5.2 Creating and Posting the Final Set of Videos .................................................................................................. 83 
7 
 
5.3 Creating Supplemental Assignments .............................................................................................................. 84 
5.4 Future Usage of the Set of Videos and Supplemental Assignments in the Classroom ..................................... 85 
CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS ......................................................... 86 
6.1 The Team’s Conclusions on the Impacts of Genome Sequencing Technologies .............................................. 86 
6.2 Future Recommendations .............................................................................................................................. 86 
REFERENCES .......................................................................................................................................... 87 
APPENDIX I: STUDENT SURVEY ...................................................................................................... 93 
APPENDIX II: FACULTY SURVEY ..................................................................................................... 96 
APPENDIX III: FEEDBACK FORM FOR VIDEO PREVIEW ......................................................... 98 
APPENDIX IV: SUPPLEMENTAL ASSIGNMENTS ......................................................................... 99 
 
  
8 
 
Table of Tables 
 
Table 1: Performance Statistics of the 454 GS FLX+System....................................................... 21 
Table 2: A Comparison of the Performance Statistics of the Illumina Genome Analyzer IIx and 
the HiSeq 2000 .............................................................................................................................. 22 
Table 3: A Comparison of the Performance of Recent Illumina Sequencing Systems ................ 25 
Table 4: A Comparison of Recent SOLiD Systems Based on Statistical Performance ................ 28 
Table 5: A Comparison of the Performance Statistics for Helicos tSMS ..................................... 29 
Table 6: A Comparison of the Performance Statistics for Pacific Biosciences SMRT ................ 31 
Table 7: The Cost of Amazon Elastic Compute Cloud................................................................. 39 
Table 8: Specifications of Bench Top Sequencers that are Available as of August, 2011 ........... 43 
Table 9: Comparison of Employment Estimation (Jobs per Year) by Sector............................... 47 
Table 10: Genome Sizes and Gene Density in Humans as Compared with Other Organisms ..... 59 
  
9 
 
Table of Figures 
 
Figure 1: A Graphic Comparing a Standard Nucleotide (a) to a Dideoxynucleotide (b) ............. 17 
Figure 2: A Graphic Illustrating How the Chain Terminated DNA Fragments Produce a 
Sequence of Bands ........................................................................................................................ 18 
Figure 3: A Graphic Illustrating Emulsion-based Clonal Amplification ...................................... 20 
Figure 4: A Graphical Representation of Illumina Library Preparation ....................................... 22 
Figure 5: A Graphic Illustrating Illumina Bridge Amplification .................................................. 23 
Figure 6: A Graphic Illustrating the Emittance of Fluorescence upon Laser Excitation .............. 24 
Figure 7: A Graphic Illustrating the Preparation of Clonal Bead Populations via Microreactors 26 
Figure 8: A Graphic of a Di-base Probe Emitting Fluorescence as Used in the SOLiD System . 26 
Figure 9: A Graphic Showing the Matrix Used to Decode the 2-base Encoding Used in the 
SOLiD System .............................................................................................................................. 27 
Figure 10: A Graphic Illustrating the Recording of Single Nucleotide Base Additions in tSMS 30 
Figure 11: A Graphic Illustrating DNA Polymerase Adding a Nucleotide and Then Cleaving the 
Fluorescent Label During SMRT Sequencing .............................................................................. 32 
Figure 12: A Graphic Illustrating the Light Emiitance Captured in the ZMW Nano-photonic 
Chamber During SMRT Sequencing ............................................................................................ 32 
Figure 13: A Graphic Showing an Overview of Sequencing Through Scanning Tunneling 
Microscopy ................................................................................................................................... 34 
Figure 14: A Graphic Showing the Relationship Between the Probes and the Substrate in 
OmniMoRA Sequencing ............................................................................................................... 35 
Figure 15: A Graphic Illustrating the Preparation of DNA Nano-balls ........................................ 37 
Figure 16: Structure of Forward and Backward Linkage Associated with the Human Genome 
Project ........................................................................................................................................... 45 
Figure 17: United States Federal Funding for Genome Related Research between 1988 and 2010
....................................................................................................................................................... 46 
Figure 18: Comparison of Employment Estimation by Sector ..................................................... 47 
Figure 19: Cost per Genome from September 2001 to September 2011 ...................................... 60 
Figure 20: An Illustration of an Example of Metagenomic Studies ............................................. 64 
Figure 21: Adoption of Transgenic Crops in USA from 1996 to 2011 ........................................ 68 
Figure 22: A Line Chart Comparing the Level of Familiarity on the Impacts of Sequencing 
Technologies of Biology Related Majors and Non-biology Related Majors ............................... 73 
Figure 23: A Line Chart Comparing the Percent of Interest on the Impacts of Sequencing 
Technologies of Biology Related Majors and Non-biology Related Majors ............................... 74 
 
  
10 
 
List of Acronyms 
 
AHEC 
AIDS 
ALRC 
ARG 
BLAST 
BB 
BCB 
BME 
bp 
CLUSTALW 
ddNTP 
DNA 
dNTP 
GB 
GINA 
G8 
HGP 
HIV 
IRB 
MB 
PCR 
RNA 
Australian Health Ethics Committee 
Acquired Immune Deficiency Syndrome 
Australian Law Reform Commission 
Ancestral Recombination Graph 
Basic Local Alignment Search Tool 
Biology and Biotechnology 
Bioinformatics and Computational Biology 
Biomedical Engineering 
Base Pair 
Cluster Alignment Interface with Weights 
Dideoxynucletide-tri-phosphate 
Deoxyribonucleic Acid 
Deoxynucleotide-tri-phosphate 
Gigabyte 
Genetic Information Nondiscrimination Act 
Group of Eight 
Human Genome Project 
Human Immunodeficiency Virus 
Instructional Review Board 
Megabyte 
Polymerase Chain Reaction 
Ribonucleic Acid 
11 
 
SBS 
SMRT 
SNP 
ssDNA 
STM 
TEM 
tSMS 
UV 
ZMW 
Sequencing by Synthesis 
Single Molecule Real Time  
Single Nucleotide Polymorphism 
Single Stranded Deoxyribonucleic Acid 
Scanning Tunneling Microscope 
Transmission Electron Microscopy 
True Single Molecule Sequencing 
Ultraviolet 
Zero Mode Waveguide 
  
12 
 
Executive Summary 
 
Genome sequencing technologies are becoming increasingly more advanced with higher 
throughputs and increased accuracy, and more applications for them are being discovered daily.  
While having a positive effect on the United States economy, these advances impact a variety of 
fields including forensics, disease diagnosis and treatment, vaccination, personalized drug 
development, genetic studies, evolutionary studies, and agriculture. However these positive 
impacts have also introduced some social issues such as the issues pertaining to ownership, 
privacy, and legislation related to the control of genetic information. The goal of this Interactive 
Qualifying Project was to research the effects genome sequencing technologies have had in each 
of these fields and then communicate them to a global audience.  
 
Online resources can play a critical role in student education as they serve to broaden the 
boundaries of a course past the information from the instructor and textbook. In addition, the use 
of multimedia to aid in student comprehension and retention is becoming increasingly common. 
Thus the team generated online educational material in regards to genome sequencing 
technologies and their various impacts in other fields.  
 
Furthermore, undergraduates at WPI were surveyed in regards to their interest, opinion, and 
familiarity with recent genome sequencing technologies and their various applications. WPI 
faculty were also surveyed, but in regards to their preferences for various aspects of our final 
deliverables as well as their interest in using our educational materials in their course(s). The 
information obtained from these two surveys enabled the team to make the educational materials 
more relevant and useful for the target demographic. 
 
The student survey results indicates that those majoring in biology related fields have a higher 
amount of familiarity with genome sequencing technologies and their impacts on medicine, 
compared to students majoring in fields unrelated to biology. In regards to interest, students 
reported to be more interested in how advances in genome sequencing technologies have 
impacted cancer research and disease treatment. The impacts of these technologies on legislation 
and the economy received the lowest amount of interest, but the team determined that this was 
resultant of the fact that students reported to have the lowest amount of familiarity with the 
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impacts in these areas. Thus, the team resolved to still include these topics of lower interest in 
the final series of videos, hoping that the team’s introduction to this field will initiate a higher 
amount of interest. 
 
Even though the level of response from the faculty survey was low, the team was able to obtain a 
lot of valuable information from conducting this survey. Foremost is the fact that instructors 
reported to prefer an educational video broken into segments rather than a full length video, due 
to more flexibility in terms of showing the videos that are most relevant to their specific course. 
Some also noted that class time was limited, and thus having the materials available online 
would be more convenient as students could be directed to watch the material and complete the 
assignments outside of the classroom.  
 
The primary component of the educational materials developed by the team was a series of 
online videos to educate people about the advances in genome sequencing technologies and the 
implications of these advances in fields such as law, forensics, medicine, and biological research. 
Most of the images and text used in these videos were created by the team members, and all of 
the video animation, script writing, and narration were also done by the team. The pieces of 
software utilized include Adobe Photoshop CS 5.1, which was used for image creation and 
adjustment, Adobe Flash CS 5.5, which was used for two-dimensional animation, and Adobe 
Premiere Pro CS 5.5, which was used to compile the animation sequences, music, narration, and 
subtitles together. Along with the creation of the visual components, a script was written for each 
segment of the video and then recorded. Approximately 35 minutes of film was made using this 
workflow.  
 
Partly in response to the faculty survey and suggestions, the team also developed a short 
assignment for each segment of the final video. The answers to most of these questions are 
contained in the series of videos, while others initiate students to conduct further research on a 
specific area and then participate in a class debate and/or discussion.  
 
The final set of videos was posted on YouTube in order to inform a larger audience. These 
videos can be accessed through the team’s YouTube Channel: 
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http://www.youtube.com/user/ImGenTechWPI/videos. This includes a playlist of the 12 
individual segments as well as a playlist with the material organized into three parts: 1
st
, 2
nd
, and 
3
rd
 Generation Genome Sequencing Technologies, Social Impacts of Genome Sequencing 
Technologies, and Impacts of Genome Sequencing Technologies Related to Medicine and 
Biological Research. All of the videos are set to public access, assuring that people all over the 
world can view the videos as long as their country has no regulations preventing them to view it. 
This will also enable educators to link to the video(s) and have their students watch it outside of 
the classroom. It was also requested of the team to send the final set of videos to the WPI 
Bioinformatics and Computational Biology program for possible future use. The description field 
underneath each video in the playlist direct instructors to email imgentech12@gmail.com if they 
wish to access the assignments related to the video.  
 
A future extension of this project would be to assess the effectivity of these educational 
materials. This could be accomplished through the creation of a focus group of students to assess 
their understanding of the various impacts of genome sequencing technologies before and after 
viewing the team’s final set of videos and completing some of the supplemental assignments. 
Another possible continuation of this project would be to create other types of educational 
materials to communicate the same information, allowing an even larger audience to benefit 
from the content. These materials could be but are not limited to interactive websites, computer 
games, and mobile applications.  
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Chapter 1: Introduction 
 
The advances in genome sequencing technologies in the last few decades have affected a variety 
of fields including the economy, disease diagnosis and treatment, vaccination, personalized drug 
development, genetic studies, evolutionary studies, forensic studies, and agriculture. However 
these positive impacts have also introduced some social issues such as the issues pertaining to 
ownership, privacy, and legislation related to the control of genetic information. 
 
It can be said that one cannot fully understand the impact a given technology can have on their 
lives without having a proficient understanding of the technology itself. As a result, in order to 
create greater public awareness on these issues, the team created a series of educational videos 
that serve as an introduction to the impact new genome sequencing technologies have had on 
these fields, while also providing an introduction to the primary genome sequencers playing a 
role in these industries. The team also conducted a survey in order to determine which topics 
undergraduate students were more familiar with, which topics they were interested in learning 
more about, and to also develop a sense of the opinions these students had in regards to the many 
impacts these technologies have on society. Furthermore, in response to suggestions made by 
faculty at Worcester Polytechnic Institute, the team also created a set of assignments to 
accompany these videos. If these components are implemented together, they will allow a 
student to gain an introduction to the technological, social, and medicinal aspects of rapidly 
developing sequencing technologies and how it affects their lives, while also being able to 
demonstrate this understanding to their course instructor through the completion of the 
assignments. All of the educational materials developed by the team were posted on the internet 
in order to reach a larger audience and have more of an impact with our project deliverables.  
 
As this field progresses, it is expected that the rapid advances in sequencing technology will 
enable further development of other fields such as medicine, government, and agriculture. Next 
generation sequencing technologies have the following technological goals: 
   
 Achieving a low cost per genome sequenced 
 Achieving faster sequencing 
 Reducing error rates 
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 Allowing for larger read lengths to facilitate assembly (for human genome sequencing) 
but also having the ability to have shorter read lengths (for the accurate sequencing of 
microbes) 
 Creating a more automated technology in order to reduce the number of lab technicians 
needed to run the sequencer and interpret the data 
 Creating flexible sequencers and software so that they can be interchanged, allowing for 
the combination of technologies to overcome their limitations 
 Decreasing the time and complexity of DNA preparation 
 Reducing the number of reagents and/or consumables involved 
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Chapter 2: Background on Genome Sequencing Technologies 
 
This chapter includes information concerning the background of gene sequencing technologies, 
including the Sanger Method, second and third generation gene sequencers, computational 
methods, and projections.  
 
2.1 The Sanger Method – 1st Generation Genome Sequencing 
The Sanger method, also known as the chain termination method, was developed by Frederick 
Sanger in 1977. This was the first practical sequencing method and was recognized as the 
method of choice since its introduction. The Sanger method has been commonly used both in 
industry and academia. Investigators of the Human Genome Project (HGP) also made use of the 
Sanger method as the basis of their sequencing technique. Various novel sequencing methods 
have evolved from the Sanger method. However, compared to the second generation methods 
and other novel sequencing methods introduced in the 21st century, the Sanger method is low in 
output and accuracy, and as a result it is no longer commonly used.  
 
In the Sanger method, dideoxynucleotides (ddNTPs),  which contain a hydrogen group on the 
three prime carbon instead of a hydroxyl group, prevent the bonding of addition nucleotides, and 
thus cause the termination of the DNA chain (Sanger, 1977). Figure 1 below is a graphic from 
our educational video comparing a normal nucleotide to a dideoxynucleotide. 
                
(a) A Normal Nucleotide with a Hydroxyl Group (b) A Dideoxynucleotide with a Hydrogen Group 
Figure 1: A Graphic Comparing a Standard Nucleotide (a) to a Dideoxynucleotide (b) 
 
First, the DNA of interest is put into solution and heated to denature. Primers are prepared by 
cutting small segments from the complementary strand. A primer is then annealed to one of the 
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template strands so that the primer’s 3’ end is located next to the DNA sequence of interest 
(Sanger, 1977). Either the primer or one of the nucleotides is radioactively or fluorescently 
labeled to be detected on a gel later. Next the primer-attached DNA solution is divided into four 
tubes labeled A, T, C, G, each containing all the dNTP, DNA polymerase, and only the 
corresponding ddNTP, which is at about 1/100 the concentration of the dNTP concentration 
(1977). As a result, the replicating DNA chains are randomly terminated at the corresponding 
nucleotide when a ddNTP is bonded to the chain, producing DNA bands of various lengths. Then 
the DNA is denatured again and run in different lanes on a polyacarylimide gel in order to 
separate the different sized bands. The DNA fragments are attracted by electrostatic force and 
the shorter the DNA fragment, the lighter the molecular weight, and thus it travels a longer 
distance across the gel (1977). Consequently, the gel provides a short-to-long array of DNA 
fragments of the same nucleotide. The gel is exposed to UV light or X-rays, and a film indicating 
the DNA sequence is produced (1977). Figure 2 is a set of graphics from our video illustrating 
the running of the DNA fragments on a gel and the resulting set of bands. In the example shown 
in Figure 2, the first 5 base sequence is A-G-C-A-T (starting from the bottom of the gel).  
                                               
Figure 2: A Graphic Illustrating How the Chain Terminated DNA Fragments Produce a 
Sequence of Bands 
 
Further improvements to the method include automated sequencing, where the ddNTPs are 
labeled with four different dyes (Obenrader, 2011). This allows for the use of one single gel lane 
instead of four separate ones and each dye fluoresces at different wavelengths, which enables 
automatic reading with lasers (2011)  
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The limitations of the Sanger method include (Obenrader, 2011): 
1. Sequencing accuracy is affected by non-specific binding of the primer to the DNA.  
2. The accuracy of the output is affected by DNA secondary structures. 
3. The method only allows for a direct reading of 300-1000 bases at a time because the 
differences in lengths become insignificant for longer DNA fragments. 
 
2.2 Second Generation Sequencing Technologies 
Second generation sequencing technologies are further advances upon the Sanger method. The 
following is a discussion of the sequencing platforms by Roche, Illumina, Inc., and Applied 
Biosystems.  
 
2.2.1 Roche 454 System 
In 2005, the 454 sequencing system was the first of the second generation sequencing platforms 
to be available as a commercial product (Shendure, 2008). The basis of this device is the 
detection of pyrophosphate, which was first described in 1985, and shortly afterwards it was 
incorporated into DNA sequencing technology (2008). The 454 method uses DNA polymerase 
and primers to create a complementary strand of DNA and then amplify it. These strands have a 
pyrophosphate group that emits a different light for each possible nitrogenous base. Therefore, 
the sequence of the light being emitted creates the sequence of nucleotides. The reading length 
for this method is higher than the Sanger method and does not involve as much time and money 
in DNA preparation, however, it still requires extensive laboratory work prior to sequencing 
(2008). Synthesizing all of the information together creates the final assembled sequence. The 
following is a summary of the steps involved in the 454 method of DNA sequencing:   
 
Generation of a single-stranded template DNA library: First the library can be constructed by 
any method that gives rise to a mixture of short, adaptor-flanked fragments (Ansorge, 2009). 
Fortunately this step can be automated and thus proves to be more convenient when compared to 
the extensive preparation involved in the Sanger method. 
 
20 
 
Emulsion-based clonal amplification of the library: Then emulsion PCR is used to amplify the 
DNA library. The amplification here is important because otherwise sufficient light signal 
intensity for detecting the reaction cannot be obtained during the sequencing step (Ansorge, 
2009). Figure 3 is a graphic from our final set of videos, illustrating this step of the process.    
 
Figure 3: A Graphic Illustrating Emulsion-based Clonal Amplification 
 
Data generation via sequencing-by-synthesis: Each bead with its single amplified fragment is 
placed at the top end of an etched fiber in an optical fiber chip, created from glass fiber bundles 
(Ansorge, 2009). In the next step polymerase enzymes and primers are added to the beads, and 
one unlabeled nucleotide is supplied to the reaction mixture to all beads on the chip, so that 
synthesis of the complementary strand can begin (2009). The base added to the sequence can be 
identified based on the light signal emitted.  
 
Data analysis using different bioinformatics tools: Compared to the Sanger method, 454 
technology allows for the analysis of 96 samples in parallel in a microtiter plate. Thus it is quite 
efficient and avoids the large use of gels or polymers that are used in the Sanger method (which 
limit the number of genomes that can be analyzed in parallel) (Ansorge, 2009). In addition, this 
method creates read lengths that are more consistent and longer than the lengths generated by the 
Sanger method, enabling more ease of assembly. It also has a high number of reads per run, and 
thus is nicknamed the “shotgun” approach (2009). The run time of less than a day and very high 
accuracy clearly attest to why this technology has been accepted and widely used (2009).  
 
A major limitation of 454 technology is that it cannot deal successfully with homopolymers, for 
example, CCC or GGG (Ansorge, 2009). The length of the homopolymers can only be inferred 
from the light signal intensity, which can lead to a greater error rate. Also, currently the per-base 
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cost of sequencing with the 454 platform is much greater than that of other platforms, such as the 
SOLiD System and Illumina Solexa. Table 1 below provides performance statistics of the GS 
FLX+ System, the series of instruments designed by 454 Life Sciences. 
Table 1: Performance Statistics of the 454 GS FLX+System  
(Data from Roche Diagnostics Corporation, 2011) 
GS FLX+ System 
Sequencing Kit GS FLX Titanium XL+ GS FLX Titanium XLR70 
Read Length Up to 1000 bp Up to 600 bp 
Mode Read Length 700 bp 450 bp 
Typical Throughput 700 Mb 450 Mb 
Reads per Run ~1 Million shotgun ~1 Million shotgun 
Consensus Accuracy 99.997% 99.995% 
Run Time 23 hours 10 hours 
Sample Input gDNA or cDNA gDNA, cDNA, or amplicons 
(PCR products) 
 
 
2.2.2 Sequencing Systems by Illumina, Inc. 
The Illumina method also uses the principle of chain termination, as described in section 2.1. 
However, it has substantial improvements in its high output, making commercial DNA 
sequencing services possible (Cappelletti, 2008). With the help of improved computation, the 
process is highly automated. By 2008, the Illumina Genome Analyzer IIx was the most advanced 
platform of the company (2008). A few years later, the company released the HiSeq 2000, which 
utilizes the same principle of sequencing. Improvements in engineering aspects, including the 
design of the platform, chemicals reagents being used and computational methods have led to 
one of the highest outputs currently available on the market (Illumina, 2011). It is important to 
note that the customizable read length of this system allows for the sequencer to be used in 
various fields (2011). Table 2 summarizes the performance statistics of these two sequencers.  
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Table 2: A Comparison of the Performance Statistics of the Illumina Genome Analyzer IIx 
and the HiSeq 2000 
(Based on data from Cappelletti, 2008 and Illumina, 2011) 
Performance Statistic Illumina Genome Analyzer IIx Illumina HiSeq 2000 
Output per Run 20-25 Gb of high quality data 600 Gb of high quality data 
6 billion reads per paired-end 
run 
Output per Day 25 Gb Data not available 
Read Length 75 base pairs Customized: 35, 50, or 100 bp 
Accuracy  98.5% Data not available 
 
The following is a detailed description of the Illumina method for sequencing, with a specific 
focus on the Illumina Genome Analyzer IIx. 
 
Library preparation: The DNA is first randomly cut into small fragments (~ 75 bases long). 
Adaptors (specially made from oligonucleotides) are ligated to the fragments. After 6 – 15 cycles 
of PCR and denaturation, a single stranded DNA library of different fragments is retained 
(Illumina, 2011). Figure 4, from Ansorge, illustrates these steps.  
 
  
Figure 4: A Graphical Representation of Illumina Library Preparation 
(Ansorge, 2009) 
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Automated cluster generation: The single stranded DNA fragments are washed over the surface 
of a flow cell, where adaptors are covalently bonded on the surface in a dense forest (Ansorge, 
2009). The single stranded fragments (with adaptors on both ends) randomly bind to the adaptors 
on the inside surface. A process called bridge amplification is conducted and allows for the 
obtaining of clusters of different fragments distributing randomly on the surface (2009). Bridge 
amplification allows the generation of immobilized copies of a specific DNA molecule on the 
oligo-derivatized surface (2009). Figure 5 below is a simplified graphic from our final set of 
videos illustrating the concept of bridge amplification. For each cluster, there are 1000 copies of 
the same DNA single strand (forward direction only) densely packed in a circular area of about 1 
um in diameter (2009).  
 
Figure 5: A Graphic Illustrating Illumina Bridge Amplification 
 
Sequencing: Next, sequencing primers (complementary to the adaptor end) and DNA polymerase 
are added into the flow cell. The four different types of ddNTPs are fluorescently labeled with 
different dyes and added into the flow cell (Illumina, 2011). Because ddNTPs terminate the chain 
growth, nucleotides are added one at a time onto the primer. Next, the excessive ddNTPs are 
washed away. For each cluster, over one thousand of the same fluorescently labeled ddNTPs are 
gathered together, which results in strong fluorescence under laser excitation (2011). Figure 6 
below is a graphic from our final set of videos that illustrates this step. The image is captured by 
a camera and analyzed by software. Next, the fluorescent dyes are chemically removed, and the 
ddNTPs are converted to normal dNTPs allowing the next nucleotide to be added (2011). These 
24 
 
steps, when combined create one sequencing cycle. The sequencing cycle is repeated to 
determine the next nucleotide on the fragments (2011).  
  
Figure 6: A Graphic Illustrating the Emittance of Fluorescence upon Laser Excitation 
 
Although it seems that adding and sequencing one base at a time is very slow, one flow cell is 
able to analyze more than 150 million clusters at a time, making the system very efficient 
(Illumina, 2011). At approximately 20x coverage, software can be used to automatically 
determine the order of the fragments in order to provide the genome-scale DNA sequence 
(2011). Table 3 below, courtesy of Illumina, compares the performance of different Illumina 
sequencing systems developed over the past few years.  
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Table 3: A Comparison of the Performance of Recent Illumina Sequencing Systems 
(Illumina, 2012)
 
 
2.2.3 Applied Biosystems SOLiD System 
 
The SOLiD method of sequencing by Applied Biosystems is different from the sequencers 
discussed previously because it can be adjusted based on the type of information desired. For 
example, mate pair libraries can be used if one is trying to find genetic rearrangements (Applied 
Biosystems, 2011). 
 
Similar to the previous method, the DNA is first amplified via PCR and fragmented, before a 
primer is hybridized to the fragment. Clonal bead populations are prepared in microreactors with 
all of the reaction reagents required (Applied Biosystems, 2011). Figure 7 below is a graphic 
from our video that illustrates this concept. More beads can be put on the slide but it can often 
result in lower output. Thus, the system is flexible based on the read length, coverage, and speed 
one desires (2011).  
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Figure 7: A Graphic Illustrating the Preparation of Clonal Bead Populations via 
Microreactors 
 
The templates are then denatured, and the beads are separated using an enrichment process that 
divides the beads with extended templates from the beads that did not react (Life Technologies, 
2011).  The ligation step utilizes di-base probes to compete for ligation to the primer. Figure 8 
below is a simplified graphic from our video illustrating a di-base probe emitting fluorescence.  
These probes have eight individual bases:  three that are degenerate, three that are universal, and 
two that are the object of interrogation (2011). 
 
Figure 8: A Graphic of a Di-base Probe Emitting Fluorescence as Used in the SOLiD 
System 
 
A 3 prime modification is performed on the fragments, which allows the beads to bond 
covalently to the surface of the slide (Applied Biosystems, 2011).  These modified beads are 
deposited on a slide.  The extension product that is generated by this process is removed, and the 
primer goes back to the previous position (N-1) in order to ligate again. Five rounds of ligation 
are completed for every single sequence tag, and the process ensures that every base is 
interrogated by two different primers in two separate reactions (2011).  
 
The data is generated based on a multi-base encoding scheme that assigns a particular color to 
four possible combinations of nitrogenous bases (Life Technologies, 2011).  Similar to the 
Illumina method, a camera passes over and takes pictures of the plates, showing the sequences 
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present.  A special matrix is prepared in order to decode these sequences, mapping out the 
possible combinations and showing the colors associated with them (2011).  This is known as 
Exact Call Chemistry (2011). Figure 9 below is a graphic from our video illustrating the matrix 
used to decode the 2-base encoding.  
 
Figure 9: A Graphic Showing the Matrix Used to Decode the 2-base Encoding Used in the 
SOLiD System 
 
One of the advantages to this system is the ease with which it detects single base insertions and 
deletions, since the entire color scheme changes completely in the region surrounding the 
breakpoint of the anomaly (Life Technologies, 2011).  The SOLiD system is also useful for 
detecting small nucleotide polymorphisms (SNPs), which are thought to denote differences in the 
phenotypes of people (2011). Table 4 below compares the most recent SOLiD systems based on 
their statistical performance.  
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Table 4: A Comparison of Recent SOLiD Systems Based on Statistical Performance 
(Data from Applied Biosystems, 2011) 
System and 
features  
5500 System 
(1.0 μm microbeads)  
5500xl System 
(1.0 μm microbeads)  
5500xl System 
(0.75 μm nanobeads) 
Application-Per-
Lane Sequencing  
Independent FlowChip lanes allow you to configure read length of 
chemistry for each lane enabling multiple applications in a single run. 
System Accuracy 
with Exact Call 
Chemistry (ECC) 
Module 
Up to 99.99% 
Multiplexing  96 barcodes for both RNA and DNA applications 
Independent 
Lanes  
1–6 
(1 FlowChip) 
1–12 
(2 FlowChips) 
1–12 
(2 FlowChips) 
Throughput 7–9 Gb/day 10–15 Gb/day >20 Gb/day 
Human 
Genomes/Run  
Up to 1 genome 
(30X average coverage) 
Up to 2 genomes 
(30X average coverage) 
Data not 
available 
Maximum Read 
Lengths  
Mate-paired: 2 x 60 bp 
Paired-end: 75 bp x 35 
bp 
Fragment: 75 bp 
Mate-paired: 2 x 60 bp 
Paired-end: 75 bp x 35 bp 
Fragment: 75 bp 
Fragment: 50 bp 
Sequencing Run 
Type  
Yield and run times for 1 lane 
Time for 1 
Genome  
1 human genome (4–5X average coverage)  7 days 
 
 
 
2.3 Third Generation Sequencing Technologies 
Third generation sequencing technologies focus on the concept of adding complementary labeled 
nucleotides one at a time in order to read the resulting sequence. The following is a discussion of 
True Single Molecule Sequencing by Helicos BioSciences and Single Molecule Real Time 
Sequencing by Pacific Biosciences.  
 
2.3.1 Helicos BioSciences True Single Molecule Sequencing (tSMS) 
Helicos technology allows for single molecule sequencing without amplification of the DNA via 
PCR) (Xu, et al., 2009). This also enables easier and shorter DNA sample preparation while 
helping to minimize the chances of error. With 20x coverage, the accuracy of Helicos technology 
is better than 2
nd
 generation technologies (2009). Table 5 below compares the performance 
statistics for Helicos True Single Molecule Sequencing in 2009 to the currently available data.  
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Table 5: A Comparison of the Performance Statistics for Helicos tSMS 
(Data from Xu, et al., 2009 and Helicos BioSciences, 2010) 
Platform Read 
Length 
Accuracy at 
20X Coverage 
Gigabases 
per Run 
Cost per Human 
Genome 
Price of 
Instrument 
Single Molecule 
tSMS Early 2009 
30-35 bp 99.995% 
 
21-28 per 8 
day run 
70,000 1.35 million 
Single Molecule 
tSMS 
Early 2011 
25-55 bp 
Average 
35 bp 
99.995% 
 
21-35 per 
day  (1 
gigabase 
per hour) 
70,000  1.35 million 
 
 
First, the DNA is broken into fragments of 100-200 nucleotides each (Helicos BioSciences, 
2010). A poly-A tail is attached to the three prime end of each fragment, in addition to a 
fluorescently labeled nucleotide. These fragments are hybridized onto the surface of a flow cell, 
which contains immobilized oligo-T-nucleotides complementary to the poly-A primer (2010). 
DNA polymerase and fluorescently labeled nucleotides are introduced into the flow cell, where 
the nucleotides are added one at a time complementary to the template fragment.  Similar to 
Illumina’s method of sequencing, a laser is used to illuminate the surface of the flowcell and 
capture the fluorescent signal emitted. However, Helicos records the addition of each nucleotide 
on a single DNA fragment as opposed to Illumina’s cluster based sequencing system. Figure 10 
below is a graphic from our final set of videos that illustrates this concept. This allows for 
billions of unique fragments to be independently sequenced at the same time (2010).  
Furthermore, the HeliScope Single Molecule Sequencer also acts as a microscope, enabling the 
nucleotides to be visually seen through proprietary fluid and optic technology (2010).  
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Figure 10: A Graphic Illustrating the Recording of Single Nucleotide Base Additions in 
tSMS 
 
A disadvantage of the Helicos technology is that it relies on reagents, which are consumable 
components of the instrument (Helicos BioSciences, 2010). Thus, purchasing the sequencer and 
software is not sufficient since the reagents need to be bought and supplied in conjunction to how 
often the sequencer is used. The errors found when testing Helicos technology are of various 
types. 0.2% were substitution errors (where a noncomplementary nucleotide was added), 1.5% 
were insertion errors (where an extra nucleotide was added and thus created a frameshift 
mutation that caused the instructions for the amino acid sequence to be completely off by one 
nucleotide per codon), and 3% were deletions errors (where one of the nucleotides that should be 
added is not added, causing a frameshift mutation (Bauman, 2010 and Helicos BioSciences, 
2010).  
 
Some interesting aspects of Helicos technology include an easy to use touch screen interface and 
multiple loading channels, which require little training on the part of the lab technician and 
versatility of experimental design, as well as the ability to remotely monitor and obtain data from 
the sequencer and software through a web application (Helicos BioSciences, 2010). This enables 
technicians to work on other activities and/or have the sequencer run over the weekend, which 
reduces the cost of labor/man power for the company. Bar code readers enable organization and 
tracking of DNA samples, which reduces the chances of samples being mislabeled by the lab 
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technician. It is also important to note that the Helicos tSMS technology can be applied to RNA, 
making it more versatile (2010). 
 
2.3.2 Pacific Biosciences Single Molecule Real Time Sequencing (SMRT) 
Pacific Biosciences’ Single Molecule Real Time Sequencing produces much larger read lengths 
compared to those produced by Helicos. This is resultant of the technology allowing the natural 
addition of phospholinked nucleotides by DNA polymerase (Xu, et al., 2009). The distinguishing 
feature between SMRT and tSMS technology is that the data from the tSMS technology is 
obtained after the 30 minute sequencing period, whereas the SMRT technology enables 
concurrent visualization of the data during the sequencing time period (Pacific Biosciences, 
2010). Table 6 below compares the information on SMRT sequencing in 2009 to the currently 
available data. 
Table 6: A Comparison of the Performance Statistics for Pacific Biosciences SMRT 
(Data from Xu, et al., 2009 and Pacific Biosciences, 2011) 
Platform Read Length Accuracy at 20X 
Coverage 
Preparation vs. 
Sequencing 
Single Molecule 
SMRT Early 2009 
1000-1500 bp 99.3% 15x coverage 
(80-85% at 1x coverage) 
Data not available 
Single Molecule 
SMRT 2011 
Greater than 
1000, up to 
10,000 at 
times 
Data not available Less than a day to 
prepare, 30 minutes 
of sequencing 
 
 
First, fluorescence is attached to nucleotides, creating phospholinked nucleotides with a different 
color for each of the four nitrogenous bases. Other single molecule fluorescent approaches have 
the fluorophore attached directly to the base, but in SMRT technology, the labeling fluorophore 
is attached to the phosphate chain, which later becomes a permanent part of the growing DNA 
strand upon cleavage by the enzyme (Pacific Biosciences, 2010). This approach makes it easier 
to detect the visual signal in real time. Figure 11 below, which is also from our final set of 
videos, illustrates how DNA polymerase cleaves the fluorescent label off during base addition.  
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Figure 11: A Graphic Illustrating DNA Polymerase Adding a Nucleotide and Then 
Cleaving the Fluorescent Label During SMRT Sequencing 
 
Thus, the short read lengths found in Helicos tSMS technology is resultant of having to start and 
stop the reaction in order to detect the visual signal, and this disruption interferes with the speed 
of DNA polymerase. The much longer read lengths produced by the SMRT method (compared 
to tSMS technology) allow for simpler and faster genome assembly (2010).  
 
A key component to SMRT technology is the zero-mode waveguides (ZMWs). ZMWs are 
simply small pores (on the order of tenths of nanometers) surrounded by metal film and silicon 
dioxide (Pacific Biosciences, 2010). Each of these acts as a visualization chamber and enables 
the detection of a single molecule amongst the many surrounding it in the sample. Figure 12 
below is graphic from our video that illustrates this concept.  
 
Figure 12: A Graphic Illustrating the Light Emiitance Captured in the ZMW Nano-
photonic Chamber During SMRT Sequencing 
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The fast detection allows for lower background noise (Xu, et al., 2009). Assembly of the 
fragments is based on common sequences. The low reagent use and the long reads reduce the 
cost of SMRT technology. 
 
2.4 Additional Sequencing Methods 
There are many additional methods of genome sequencing arising in industry as well. Many of 
these technologies are less competitive in the market. Competition brought by other concurrent 
DNA sequencing technologies that are often more accurate and cheaper have led to the cease of 
published innovation by a few of the companies mentioned in this section.  However, these 
different methods target the sequencing of different lengths of DNA and produce different levels 
of accuracy, and thus can be tailored according to the specific need. The following is a summary 
of these methods and their advantages and disadvantages.  
 
2.4.1 Direct Sequencing via TEM by ZS Genetics 
Direct sequencing via transmission electron microscopy (TEM) also involves PCR 
amplification, similar to the 2nd generation sequencing technologies previously discussed. 
Nucleotides are previously labeled, with four respective heavy elements such as iodine, and their 
attachment to a substrate is captured through a transmission electron microscope (Xu, et al., 
2009). This microscope is based on contrast, and the heavy element is apparent compared to the 
other elements such as carbon and hydrogen that are part of the DNA (2009). Some issues with 
this technology include that the speed is limited by the speed of the camera, it involves prior 
preparation of the DNA and reagent samples, and that it has a high initial capital cost since 
TEMs can cost about 1 million dollars each (2009).  
 
2.4.2 Nanopore Sequencing 
In nanopore sequencing the single stranded DNA (ssDNA) molecule is electrically driven 
through a nanoscale (on the order of 10^-9 meters) pore and the change in electrical signals 
dictates the DNA sequence (different electronic signal from each of the bases) (Xu, et al., 2009). 
However it was found to have much noise in the electrical signal, while requiring high sampling 
rates (2009). The final reading is also dependent on the velocity of the DNA driven through the 
pore. On a higher note, this technology has a relatively low cost (2009).  
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2.4.3 Electronic Scanning Tunneling Microscopy (STM) 
In STM, an electrical vacuum is created, and a sharp metal tip is brought into contact with the 
surface of the DNA sample. This generates a current on the order of nA (nano-Amperes), which 
is then translated into an image based on current density (Xu, et al., 2009). However, many 
limitations come with this technology, including the consistency of the DNA sample preparation 
(prior to sequencing), the fragility of the DNA (when straightening and stretching the DNA 
sample on a surface, and also knowing the optimum location for the start of the sequencing 
because different start locations have given the researchers different results (Schadt, et al., 2010). 
Figure 13 below, from Schadt and his colleagues, illustrates this method of sequencing.   
 
 
Figure 13: A Graphic Showing an Overview of Sequencing Through Scanning Tunneling 
Microscopy 
(Schadt, et al., 2010) 
 
2.4.4 NanoKnife Edge Probe Method by Revase 
The NanoKnife Edge Probe method of sequencing is commercially known as OmniMoRA 
(Omni Molecular Recognizer Application) by ReVase. The single stranded DNA is first 
stretched and immobilized in a small channel (on the order of micrometers) (Defense Tech 
Briefs, 2009). Each electrically conductive probe lines up with a DNA base, excites it 
electrically, and then recognizes the vibrations produced by the DNA base in response to the 
electrical signal (2009). Each nitrogenous base has a different vibrational pattern, allowing 
physical detection of individual bases. When the probe comes in contact with the wrong base in 
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the sequence, there is no current detected (Xu, et al., 2009). Figure 14 below, courtesy of Blow, 
shows the relationship between the probes and the substrate.  
 
Figure 14: A Graphic Showing the Relationship Between the Probes and the Substrate in 
OmniMoRA Sequencing 
(Blow, 2008) 
 
There was also the possibility that this technology would allow the detection of the placement 
and presence of methyl groups on the genome, which help regulate whether a given gene is 
expressed (Defense Tech Briefs, 2009). Methyl groups are also thought to be linked to cancer 
formation, so this technology has impacts beyond genome sequencing (2009).  
 
This technology has its limitations as well. First, much of the research is focused on how to 
consistently manufacture and use the probe nano-nozzles (Xu, et al., 2009). In addition, they are 
also looking into incorporating optical, magnetic, and electric stimuli into the probes, thus 
enhancing the detecting signals (2009). The cost of the nano-knife-edge probes must also be 
reduced before the technology can be used widely. In addition, to reduce detection errors, it has 
been proposed that each nucleotide be measured with 64 sets of the four nano-knife edge probes 
and to use a fifth probe to detect a methyl group (Blow, 2008). This degree of accuracy warrants 
high cost; thus compared with other methods such as Helicos tSMS, it is not as competitive in 
the market (Blow, 2008). The company did report to have a high accuracy (99.9%), but this level 
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of accuracy has been reached by other sequencers as well (Zimmerman, 2008). The current goal 
of the company is to be able to sequence 100 genomes in less than 10 days, for $10,000 per 
genome (2008). 
 
2.4.5 Sequencing by Synthesis (SBS) by Intelligent Biosystems 
Intelligent Biosystems has developed the Sequencing by Synthesis (SBS) method which begins 
with amplification of DNA fragments via PCR. The prepared DNA fragments are contained in 
flow cells that are loaded into the sequencer (Intelligent BioSystems, 2011). The nitrogenous 
bases being added to the growing strand are previously prepared to contain an end cap as well as 
a fluorescent dye that acts as a label (each type of nucleotide has a different removal dye) (Ju, et 
al., 2006). The fragments are then affixed as an array of spots on a glass chip and treated with 
reagents including the previously prepared nitrogenous bases, which attach to each of the spots 
and extend the growing strand of DNA based on the complementary strand. A camera is used to 
measure the fluorescent dye as it is cleaved (along with the end cap) and the information is 
recorded to identify the base that was added (2006).  
 
However, the labeling method of SBS introduces issues during the addition of nucleotides to the 
growing strand by DNA polymerase. This can lead to varying and/or short read lengths, and 
potential errors (Tettelin and Feldblyum, 2009). Labeling nucleotides also makes the preparation 
time longer and more costly (2009).   
 
2.4.6 DNA Nano-ball Method 
Similar to many of the other sequencing methods, this method begins with creating DNA 
fragments with restriction enzymes and amplifying them with PCR, producing hundreds of 
coiled single-stranded DNA. Figure 15 below, courtesy of Mohankumar, shows this step 
graphically. These DNA Nano-balls are placed in an array and read starting from 10 bases away 
from the site of anchoring (Drmanac, 2009). 
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Figure 15: A Graphic Illustrating the Preparation of DNA Nano-balls 
(Mohankumar, 2011) 
 
The read length for this method is 62-70 bases (Drmanac, 2009). This method was used to 
sequence three human genomes, two of which had been previously sequenced using other 
technologies.  An alignment algorithm was used to assemble the sequence reads, and 
representational biases were assessed in order to check base coverage statistics (2009).  
Reportedly, calls were made with some confidence, and many of the errors found were 
discovered to be errors made in the reference genomes.  Overall, this process costs 
approximately 4400 dollars and thus proves to be very affordable (2009).  
 
However, there was a significant issue with errors in the genome sequencing while using this 
process. Occasionally, aberrant mate-pair gaps appeared which would often lead to length 
altering structural variants as compared to the reference genomes (Drmanac, 2009).  Another 
source of error in most methods came from the fact that N+1 sequencing methods were used, 
meaning that the accuracy of one sequence is dependent on the last (2009).  This could cause 
initial errors to cause increasing inaccuracies and carry forward large amounts of errors. 
 
2.5 Computational Methods 
Currently two factors are crucial to the development of next-generation DNA sequencing 
technology: the biological methodologies as well as the computational power. It is important to 
find reliable and efficient ways to interpret large data and obtain meaningful results. Currently 
there are several popular areas in which computation power plays an important role. For 
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example, For example, data mining of DNA databases is necessary to associate certain genes to a 
disease (Dennis, 2009). With the computation capabilities of computers almost doubling every 
year, more research is being performed in this area in order to find better algorithms to match the 
large amount of data acquired by current DNA sequencing technologies (2009). 
 
2.5.1 Computational Challenges Posed by New Genome Sequencing Technologies 
Foremost of the challenges posed by the advances in sequencing technologies is the large data 
storage requirement for the sequencing results. For example, Illumina’s Hiseq 2500, which was 
released in Jan, 2012, has the output of 120 GB of data in 27 hours (Dennis, 2009). In addition, it 
is estimated that for 20-60 GB results data, a total of 56 TB raw data is involved (2009).  
 
Second is the need for faster processing and interpretation of DNA sequencing results. Next 
generation sequencers can now produce large amounts of data in the form of short reads every 
hour, thus requiring heavy computational analysis (Rusk, 2009). More efficient software tools 
and high-performance hardware are needed to meet the ever-increasing demand.   
 
2.5.2 Data Processing and Management 
To address the demand for large storage and hardware computing power, cloud computing is 
now widely used in industry.  Clouds are a large pool of easily usable and accessible virtualized 
resources (such as hardware, development platform or services) (Dennis, 2009). These resources 
can be dynamically re-configured to adjust to variable load (2009).  
 
There are several advantages cloud computing can bring to sequencing data processing and 
management. First is the incomparable computing power it possess, since an entire computing 
task previously performed by a single super computer can now be processed by a cloud of 100 
computers, which often offers more computing power and increased reliability. In addition, 
cloud computing reduce the cost significantly in terms of the storage hardware and has a 
relatively low cost for its computing capacity. Table 7 below shows the cost of Amazon Elastic 
Compute Cloud based on the operating system used.  
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Table 7: The Cost of Amazon Elastic Compute Cloud  
(Amazon Web Services, 2012) 
Standard On-Demand Instances Linux/UNIX Usage Windows Usage 
Small (1 core, 1.7GB memory & 160 GB 
storage)  
$0.080 per hour $0.115 per hour 
Large (4 cores, 7.5GB memory & 850 GB 
storage) 
$0.320 per hour $0.460 per hour 
Extra Large (8 cores, 15GB memory & 
1690 GB storage) 
$0.640 per hour $0.920 per hour 
 
 
Furthermore, currently the cost of cloud computing is decreasing by 15% every year (Dennis, 
2009). Thus, it is expected that the price will continue to drop over time. This technology also 
allows users to enjoy the flexibility provided by being able to choose the type of sever, operating 
system and CPU power that best matches the requirements of their task.  
 
2.5.3 Analyzing Sequence Data 
Sequencing analysis is the process of using various analytical methods to find the structure, 
features and functions associated with the particular genomic sequence. This includes sequence 
alignment, searches against a biological database, and sequence assembly (Durbin, 1998).  In 
order to process the large output of data in genome sequencing technologies, almost all of the 
algorithms currently being used employ a heuristic method, which provides the largest number of 
possible results (Dennis, 2009). Thus, there is always a relationship between sensitivity and 
speed. In most cases, this function relationship can be represented by a curve.  
 
In addition, computational methods are necessary for the final assembly of the genome, once 
each fragment is sequenced. The heuristic algorithm is commonly used along with a scoring 
system to evaluate each set of bases obtained by the sequencer (Dennis, 2009). The number of 
bases evaluated at a time as well as the possibility of errors is also related to the sensitivity of the 
algorithm. Higher sensitivity also can result in lower speed, thus there is a trade-off between 
having a faster method of sequencing a genome and having an accurate assembled sequence 
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2.5.3.1 Sequence Alignment 
A large part of DNA sequencing analysis lies in the alignment of these sequences. Sequence 
alignment refers to a way of arranging sequences of DNA, RNA, or proteins in order to identify 
similarities between them (Mount, 2004). These similarities can be resultant of several factors, 
including the function, structure, and evolutionary history between the sequences (2004). Thus 
sequence alignment is the key to finding important regions and determines the function of each 
part. Global sequence alignment refers to comparing both sequences up to their complete length, 
while local sequence alignment only does the searches in conserved regions (2004). The 
following is an example of alignment, where there are 6 matches, 4 gaps, and 1 mismatch 
(Batzoglou, 2006). 
A--TGG--ACGT-- 
ACTG--CCCGTA 
 
According to a scoring function, every match, gap, and mismatch is associated with a score to 
determine the proficiency of the alignment, as shown in the example equation below (Batzoglou, 
2006).  
Score F = (# matches)  assumed match – (# mismatches)  assumed mismatch – (#gaps) 
 assumed gap 
 
Often an aligner is needed during DNA sequencing analysis. In other words, upon acquiring the 
genome sequence of a patient with a given disease, an aligner is required to find what particular 
part of the genome is actually causing the disease. Two of the most widely used algorithms to do 
sequence alignment are BLAST and CLUSTALW.  
 
2.5.2.2 BLAST Algorithm 
The abbreviation, BLAST, stands for Basic Local Alignment Search Tool. This algorithm is 
mainly used for searching and comparing sequences. BLAST is one of the fastest comparing 
algorithms since it emphasizes speed rather than sensitivity (Gish, 1990). Due to how new 
genome sequencing technologies have a higher throughput, an algorithm with high speed but 
lower accuracy is often preferred (Gustav, 2007). The key to its high speed lies in the fact that 
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BLAST uses a heuristic method, which means it make a guess about the possibility for there 
being a match, thus improving the searching speed greatly (2007). 
 
BLAST and many other algorithms primarily use a similarity search because it allows for the 
identification of conserved functions (Eddy, 2004). The output of a BLAST program consists of 
many parts, including a header, graphic overview, description, alignment, and statistics (2004). 
Also one advantage of BLAST is that parameters can be changed to improve the speed, but of 
course lower sensitivity comes with the higher speed (2004).  
 
Based on the advances being made in the field of genome sequencing technology, it is believed 
that people will either continue to modify BLAST, or simply develop a new algorithm with 
higher speed and relatively satisfactory sensitivity. If routine sequencing of individual human 
genomes becomes a reality in the future, a faster algorithm is required, as well as a biological 
method with higher throughput.   
 
2.5.2.3 CLUSTALW Algorithm 
CLUSTALW, which stands for Cluster Alignment Interface with Weights, is another way to find 
the alignment between short read lengths. This algorithm is widely used for multiple sequence 
alignment (Thompson, et al., 1994). Sequence alignment refers to the arranging of DNA 
sequences to identify the similarity of a given region, which is often the functional region (1994). 
In this algorithm, individual weights are assigned to each sequence in partial alignment in order 
to distinguish the difference between similar and divergent sequences (1994).  
 
2.6 Combining Sequencing Technologies 
There has also been research into the possibility of combining different sequencing technologies 
in order to overcome the limits of each technology when used on its own. For example, when 
Roche 454 technology was combined with the Sanger method it enabled the amplification of 
DNA fragments that cannot propagate in an E. coli host, since 454 does not rely on the use of 
this host (Tettelin and Feldblyum, 2009). However the limitation of 454 with sequencing large 
homopolymers (large sequences of a repeated single base) can be overcome with the Sanger 
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method that produces more accurate results when it comes to homopolymers (2009).  As a result, 
combining sequencing technologies allows each to compensate for the limitations of the other.  
 
Unfortunately, combining these technologies introduces many issues as well. For one thing the 
data from these machines are quite large and are accompanied by the issues of data storage, in 
addition to each sequencer often having differing software applications that can process and 
analyze the output of each sequencer. In addition, the differences in accuracy, read length, and 
DNA preparation can make it difficult for the results of a combined method to be reliable and 
consistent.  
 
2.7 Projections 
In order to meet the goals for the next generation of sequencers, as stated in Chapter 1, engineers 
are now researching methods of modifying the current equipment to allow for more convenience 
for the user while creating higher amounts of accurate and fast output. Some of these 
investigators are considering adding a “bar code like” feature to DNA sequencing machines so 
that they can differentiate between matching target DNA from different people (Wright, et al., 
2011). Currently, many sequencers enable the simultaneous sequencing of multiple samples, 
often through having several channels, but it is difficult to differentiate between matching 
samples of target DNA.  As a result, adding DNA bar code tags (labeled molecules) to the ends 
of DNA fragments during the library preparation would enable the tracking of individual patients 
(2011).  
 
 Many of the DNA sequencers currently being manufactured and sold are ideal for large 
sequencing centers instead of small research and clinical laboratories. These large systems are 
also too expensive of an investment (in terms of capital) for small laboratories and companies as 
well. As a result, some companies are now developing smaller bench top genome sequencers that 
are more affordable and take up less space (Wright, et al., 2011). Table 8 provides information 
on the currently available bench top sequencers.  These, however, are more geared towards small 
genome sequencing (bacterial), and PCR product sequencing (fragments of larger genomes). The 
goal is to design bench top sequencers that are able to sequence whole human genomes (2011).  
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Table 8: Specifications of Bench Top Sequencers that are Available as of August, 2011 
(Data from Wright, 2011) 
Platform Real Length Run time Output (per run) 
Mi-Seq (Illumina) 1x35 bp 
2x100 bp 
2x150 bp 
4 hours 
19 hours 
27 hours 
120 MB 
680 MB 
1 GB 
GS Junior (Roche) 400 bp 10 hours 35 MB 
PGM (Ion Torrent)  100 bp 1-2 hours 1 GB 
 
It is thought that the future of algorithms used in genome sequencers may have modifications in 
the following fields in order to meet the demands of the improvements in new genome 
sequencing technologies. In most heuristic algorithms there is a scoring mechanism used as the 
criteria to evaluate each word, which is directly related to the sensitivity of the algorithm 
(Dennis, 2009). Thus, improving the scoring mechanism can directly result in improved 
sensitivity. Also the statistics model can be improved to better reflect the needs of the user. 
Improving the statistics model may allow users to be able to adjust the sequencer to produce the 
sensitivity desired.  
  
44 
 
Chapter 3: Impacts and Applications of Genome Sequencing 
This chapter includes research on the social impacts and medical applications of next generation 
gene sequencing technologies.  Advances in this field exercise significant influence in the 
economy, legislation, forensics, health care, biological studies, and agriculture.  
 
3.1 Economy 
Research in genome technologies has brought tremendous impacts to economy and industry. 
These economic impacts consist of three parts: direct impacts (regarding specific expenditures), 
indirect impacts (regarding suppliers), and induced impacts (regarding the additional economic 
impacts from the spending of suppliers and employees in the overall economy, as well as the 
additional industries enabled by advances in genome sequencing technologies) (Battelle 
Technology Partnership Practice, 2011).  
 
Figure 16 below, courtesy of Battelle Technology, is a diagram showing the structure of forward 
and backward linkage associated with the Human Genome Project (HGP), and highlights the 
many fields that have grown due to the advances in genome sequencing technologies. An 
assessment report on the economic impacts of genome research from Battelle was made 
available in 2011, which draws most data from government statistics. According to the findings 
in this report, between 1988 and 2010 the human genome sequencing projects in the United 
States (not constrained to just the Human Genome Project) generated an economic output of 
$795 billion (Battelle, 2011). These projects created 3.8 million job-years of employment and 
$244 billion of personal income (2011).  The indirect and induced outputs are far beyond this 
direct output.  
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Figure 16: Structure of Forward and Backward Linkage Associated with the Human 
Genome Project 
(Battelle, 2011) 
 
 The reported federal investment from the U.S. government during the period of the Human 
Genome Project was $5.6 billion (Battelle, 2011). Further investment on genome technology 
research after the HGP between the years of 2004 and 2010 was 28% more than the original 
investment (2011).  This investment was the foundation to generating the economic output of 
$795 billion above, and thus shows a Return on Investment to the U.S. economy of 141 to 1. In 
other words, every $1 of federal investment contributed to the generation of $141 in the nation’s 
economy (2011).  In 2010, the total genomics-driven output is $265 billion (2011). Figure 17 
below is a graph illustrating the increase in U.S. federal funding towards genome related research 
between the years of 1988 and 2010.  
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Figure 17: United States Federal Funding for Genome Related Research between 1988 and 
2010 
(Data from Battelle, 2011) 
 
There are six major sectors within genomics related research: Research and Development 
(R&D), Instruments and Equipment, Related Biologics and Diagnostic Substances, Related 
Testing, Related Pharmaceuticals, and Related Bioinformatics (Battelle, 2011). A comparison 
table of employment estimation of the sectors is shown below in Table 9.  Figure 18 illustrates 
this information in a graph.  
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Table 9: Comparison of Employment Estimation (Jobs per Year) by Sector  
(Data from Battelle, 2011) 
Genomic Sector 2010 2003 2000 1992 
Genomics R&D and Related 
Biotechnology 
13,323 13,140 8,275 2,378 
Genomic Instruments and 
Equipment 
11,704 15,727 10,957 9,917 
Genomics-Related Biologics and 
Diagnostic Substances 
7,234 9,427 7,145 2,243 
Genomic Related Testing 5,142 1,644 1,301 542 
Genomics-Related 
Bioinformatics 
792 1,430 667 174 
 
Pharmaceutical sector R&D 2010 2003 2000 
Genomics-Related Pharmaceutical 
R&D 
9,109 2,337 743 
 
 
 
 
 Figure 18: Comparison of Employment Estimation by Sector 
 (Data from Battelle, 2011) 
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As illustrated by the data, genomic instruments and equipment is the primary influencing factor 
among all of the sectors, followed by genomics related research and development and genomics 
related pharmaceutical research. The drop in employment seen in Figure 19 is resultant of the 
completion of the HGP (Battelle, 2011). The recent economic recession has also dampened the 
employment in the field of genomics.  On the other hand, the investment and economy output 
continued to increase after the completion of the HGP. In addition, the genomics-related share of 
the pharmaceutical industry has continued to significantly grow in both employment and output 
since 2003. 
 
3.2 Worldwide Legislation Regarding the Release of Genetic Information 
The advent of faster and more available human genome sequencing has led many countries 
around the world to consider creating legislation to either protect the privacy of individuals who 
are sequenced, and/or to assure that information from one’s genome is not used in way that 
creates detrimental consequences to the sequenced individual. Other issues such as sequenced 
minors and the genetic information of the deceased also create controversy.  
 
3.2.1 Implications of Genome Ownership, Privacy, and Disclosure 
 A majority of the genome sequencing performed today involves informed consent. One issue 
with informed consent is that individuals giving consent for their genetic information to be 
reviewed by others cannot foresee all of the consequences of this action and assess them prior to 
making the appropriate decision (Wright, et al., 2011). As a result there is a limitation of the 
word informed in the phrase informed consent. For example, a person may be asked by an 
employer to disclose their genetic information to see if they have a predisposal for a given 
disease and whether they require a vaccine prior to working in the laboratory. The patient may 
consent, knowing that they do not have a history of that disease, but may face consequences if 
the employer finds that the employee has a predisposal to cancer and thus does not want to hire 
him/her anymore on the assumption that the employee may have to leave work for treatment in 
the future.  
 Another issue is not always being able to obtain complete family consent (Wright, et al., 2011). 
For example, a patient may wish to have a gene therapist create a pedigree and inform them on 
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the chances of the patient’s child being born with a particular condition. In this case, the patient 
may be okay with releasing his/her genetic information, but the other family members who are 
also involved in the development of that pedigree may not all wish to give consent. It is also 
difficult when the family member in question is deceased because one cannot assume that 
releasing their genetic makeup would be according to the wishes of the deceased person 
(2011).  Similarly, it is difficult to prevent one from drawing conclusions based on seeing non-
genetic data that pertains to rare disorders, which can be linked to diseases that can arise in the 
future.  It can also be difficult to prevent someone from drawing conclusions from a donor 
profile (in regards to organ and blood donation) (2011). 
The process of obtaining consent for the release of genetic information can be further 
complicated if the patient involved is a minor. For example, the parents may agree to the release 
because it may enable other clinicians and analyzers to help the child in regards to a treatment of 
a disease, but the child may grow up to regret that release of genetic information if it prevents 
him/her from gaining proper health insurance even after they are completely healthy (Wright, et 
al., 2011).  
Some patients may also not wish to know if they are predisposed to certain diseases. The “right 
not to know” must also be respected. In one case, James Watson, one of the Nobel Prize winners 
for the discovery of the structure of DNA, agreed to have his genome analyzed and available to 
the public except for a particular protein that links to Alzheimer’s disease, because he personally 
did not want to know whether he was predisposed to it or not (Wright, et al., 2011).  
Furthermore, medical records are increasingly becoming electronic in an effort to reduce the use 
of paper, and to increase productivity by allowing for faster searching. However, with medical 
data (including data from whole or partial genome sequencing) being electronic, an additional 
level of security is needed to surround these files in order to prevent unlawful access to patient 
information. As a result, advances and availability of genome sequencing causes growth in the 
electronic security industry but also induces fear in some patients who may be concerned that 
their information will not remain confidential despite laws such as GINA (which is discussed in 
section 3.2.2) due to the records being electronic. One proposed solution for this is to have 
patients give consent for disclosure prior to genetic testing, since it is very difficult to keep that 
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information private once it is obtained and analyzed (Wright, et al., 2011). In this way, all tested 
patients would have their genetic information available in a database and they would be fully 
aware of this prior to agreeing to have their genome sequenced. Another solution to the issue of 
securing electronic medical records that contain genome data and analysis results is to make that 
part of the record available only at certain times and to certain professionals to minimize the 
leaking of information ( 2011).  
In any case, the line needs to be drawn between releasing genomic data (even if the patient gives 
consent) for research purposes and releasing it for clinical purposes (treating the patient for 
instance). In some cases, the clinician is conducting his/her own research, so it can be extremely 
difficult to differentiate between whether the patient is releasing the information for personal 
purposes or to further the purposes of others. 
 
3.2.2 Legislation in the United States 
Advances in new genome sequencing technologies also introduce questions of intellectual 
property. With genome sequencing, one can now patent the sequencing technologies, specific 
sequences of DNA and regulatory RNA, diagnostic test kits, chemical reagents, and other 
components of genome sequencing. However, different countries provide different amounts of 
protection for intellectual property, and whole genome sequencing can sometimes cross 
international borders (Wright, et al., 2011). The information obtained from whole genome 
sequencing may also interfere with existing patents in regards to diagnoses, treatments, and 
prevention procedures in medicine.  
 
Fortunately, the United States Genetic Information Nondiscrimination Act (GINA) prohibits 
health insurance and employers from discriminating on the basis of one’s genetic makeup (U.S. 
Department of Health and Human Services, 2009). However, it does allow employers to keep 
genetic information in individual personnel files as long as the employees have allowed for the 
disclosure of that information and it is clear that they are not obligated to disclose their genetic 
information (National Library of Medicine, 2012). This type of information includes prenatal test 
results, ancestry and predisposal to certain diseases, and paternity test results (2012). It also 
prevents employers from requiring potential employees to have genetic tests done without 
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justification (2012). The initial act was introduced in 2008, but many revisions and provisions 
have been added since.   
 
In addition to GINA, which is a federal act, many states also have related laws that vary in how 
protective they are. One limitation of GINA is that it does not refer to insurances other than 
health insurance, such as disability insurance and life insurance (Department of Health and 
Human Services, 2009).  It also does not always cover companies with fewer than fifteen 
employees (2009). 
 
3.2.3 Legislation in Europe 
In addition to the United States, Europe is also taking part in developing a relationship between 
genome sequencing technologies and their application to the health care system. However, 
countries in Europe differ in their attitude towards genetic testing. Currently, there is no 
uniformed legislation against genetic discrimination by the European Union (Borry, 2008).  
The countries of the United Kingdom and Belgium allow direct-to-customer genetic tests to be 
provided by private companies. Previously in the UK, genetic tests were confined to only 
specialized clinics and the information could not be used by employers or insurance companies 
(GeneWatch UK, 2006). Therefore there was no legislation to prevent discrimination according 
to genetic make-up. But in recent years, direct-to-customer testing has come into the market, and 
many genetic discrimination cases, especially those in the U.S., have raised the debate in the UK 
as to whether genetic discrimination should be prohibited by the law (BBC, 2011). As a result, 
the 2010 Equality Act restricts the use of genetic tests by employers and insurance companies. It 
can be seen that the UK is moving in the same direction as the United States in regards to this 
issue.  
On the other hand, some European countries ban direct-to-customer genetic tests completely. 
This group of countries includes Germany, France, Portugal and Switzerland (Borry, 2008). 
Legislation has been made so that genetic tests can only be carried out through a medical doctor 
with the consent of the patient. In addition, the doctor must inform the patient of how meaningful 
the test is and what the possible consequences will be. In a statement from the Council of Europe 
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in 2003, it was pointed out that many ethical, social, and legal issues have been raised by directly 
marketing genetic tests to customers (2008).  
Overall, most European countries show concern regarding the usage of genetic information. 
Though their aims to avoiding issues regarding genetic discrimination are similar, countries 
differ in how they specify the manner and degree of the legislation. Some countries elect to form 
general regulations and leave the details for special committees. Whether centralized legislation 
at the European Union level will form remains to be seen.  
 
3.2.4 Legislation in Australia 
Genetic research is also developing quickly in Australia.  In 2007, more than 220 genetic tests 
were available for the use in medical diagnosis and risk (Sandra, 2007). As a result, cases of 
genetic discrimination started occurring rapidly. Reports show that by the year 2000 there were 
48 anonymously reported cases of genetic discrimination in Australia, including cases involving 
life insurance and employment (Stewart, 2010). This issue has since then drawn public attention 
and the government took action by creating the Australian Law Reform Commission (ALRC) 
and the Australian Health Ethics Committee (AHEC) to conduct a comprehensive inquiry in 
terms of protecting genetic information (2010).   
It is important to note that Australia has a national health care system that is not risk-rated. Also 
unlike the US, there is no direct relationship between employers and insurance agencies, which 
causes the government to use a different approach to solving this issue (Stewart, 2010). 
In terms of health insurance, the ALRC and the AHEC state that little change needs to be made 
in the current legislation (Stewart, 2010). It is held that genetic information obtained from 
personal and family genetic testing is no different from any other information for insurance 
purposes. This opinion legalizes private insurers to take genetic information into consideration 
when offering their insurance products.  
However, in regards to employment, the ALRC and the AHEC recommend that some changes 
should be made to the current legislation (Stewart, 2010). Even though there is little information 
showing that employers in Australia are using genetic screening, it is inevitable that employers 
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will someday try to make use of the new technologies as the cost decreases and the results 
become more reliable. These committees suggest for the prohibition of employers using genetic 
testing except for rare cases where the health of employees are closely related to the working 
environment (2010). 
Thus, even though the Australian government has not yet incorporated genetic discrimination 
into legislation, it does accept the recommendations made by the ALRC and AHEC. As a result, 
it can be expected that changes will eventually be made to the federal legislation. 
 
3.2.5 Legislation in Japan 
Unlike the countries previously mentioned, Japan currently lacks a regulatory framework to 
control how genetic information is used (Porter, 2010). While the idea of prohibiting genetic 
discrimination has been mentioned in some guidelines; there is no restriction on insurance 
companies and employers regarding how they can make use of results from genetic testing 
(2010). However, this situation has not yet caused many reported incidences genetic 
discrimination.  
 
3.2.6 Legislation in China 
Furthermore, China has not created any legislation in terms of preventing genetic discrimination 
and it seems that this situation will not change in the next few years. However, there are several 
reasons behind this. Foremost is the fact that there is a low amount of public awareness regarding 
the application of genome sequencing technologies in the medical field (Mao, 1998).  Though 
China built the Beijing Genomics Institute in 1999, which is one of the premier genome 
sequencing centers in the world, this institute is mostly focused on research projects such as the 
Human Genome Project, SARS Project, and the sequencing of plants and animals (Beijing 
Genomics Institute, 2012).  In addition, due to the lack of funding and expertise, genetic services 
in China are still underdeveloped (Mao, 1998).  
Moreover, cases of genetic discrimination usually occur in fields like insurance and employment. 
Unlike the United States, China has a different policy regarding insurance and pensions, where 
employers pay directly the country’s government instead of private insurance companies, and the 
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government then distributes this to employees where applicable (Mao, 1998).  As a result, few 
cases of genetic discrimination by insurance companies have been reported.  
But rare occurrences of genetic discrimination in employment do exist. It has been reported that 
China’s first claim regarding genetic discrimination in 2010 was unsuccessful (Isaacs, 2010). In 
this case, three civil servant candidates sued the Foshan Human Resources and Social Security 
Bureau in Guangdong Province for allegedly discriminating against them during the recruitment 
process on the basis that they have a gene predisposing them to thalassaemia (a blood disease) 
(2010). The local court eventually ruled in favor of the employer based on the fact that 
thalassaemia can be a severe disease. However, this ruling seems contradictory to the fact that 
China protects carriers with Hepatitis B from discrimination through the legislation, due to the 
large number of people in China that are afflicted with Hepatitis B (Isaacs, 2010). It remains to 
be seen how legislation will develop as more cases of genetic discrimination in employment 
occur in the future.  
 
3.2.7 Legislation in Developing Countries 
There is much less debate over genetic discrimination in developing countries. It is reported that 
there were approximately 5500 genetic specialists in 1998 across the world, and 3300 of them 
worked in developed countries (Mao, 1998). This situation has not changed significantly over the 
years since this statement due to the fact that genetic research is a privilege of developed 
countries. Unfortunately, developing countries have other more pressing issues to address such 
as poverty, poor health care, and illiteracy before they can address issues relating to gene 
sequencing.   
 
3.2.8 Cultural and Religious Barriers 
Another ethical issue relating to the advances in genome sequencing technologies is the 
cultural/religious barriers. Since genome sequencing technologies are turning something that was 
perceived as a rare and expensive occurrence into a more affordable, versatile, faster, and useful 
method in medicine, the future of whole genome sequencing may encounter interference from 
various religions and cultures. For example, if based on genome sequencing a doctor determines 
that the best way to treat an infant’s genetic disease is to develop a personalized drug, the 
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parent(s) may disagree stating that doing such an act interferes with “God’s Will” (Wright, et al., 
2011). As a result, even though whole genome sequencing technologies seems to be growing at a 
logarithmic rate, it could be easily halted by religious and cultural issues.  
 
3.3 Forensics 
The DNA sequencing of loci has been useful in both solving cases and identifying the remains of 
victims. Specifically, the advent of second and third generation sequencing technologies have 
had an immediate impact on the field of forensics. In fact, Dr. Mitchell Holland and his 
colleagues used the 454 Genome Sequencer FLX  to analyze the ability to get reliable sequence 
data from STR and Y STR loci as well as look at mitochondrial DNA sequences all in a single 
reaction (Holland, et al., 2011). This allowed for the identification of certain loci using the 
binding of primers and for the using of sequence based barcodes to identify individuals (2011). 
The significant aspect about this is that this team claimed to be able to analyze many loci and 
hundreds of individuals in a single run of the genome sequencer (2011). They also claim that 
fragment length is not a factor, making more sensitive systems possible. The pros of this system 
are an increased discrimination potential and a low cost solution. 
 
Moreover, Casework Genetics is using Illumina technology in forensic applications as well. 
Specifically, Casework Genetics used the Illumina Infinium HumanOmni 1-Quad BeadChip in 
their genotyping operations, and were able to genotype over a million SNP’s per sample 
(Illumina, 2011). Typically, short tandem repeat polymorphisms are used for DNA 
fingerprinting, which involves bases that are repeated multiple times, and this region of bases 
being searched out using PCR amplification and gel electrophoresis (2011). However, this 
method is noted as being slow and does not solve the issue of mixed samples. Casework 
Genetics views searching out single nucleotide polymorphisms, also known as SNP’s, as the 
future of forensics, as SNP’s are highly conserved within populations, and as such are fairly 
unique (2011). It was also found that using the Illumina Infinium HumanOmni 1-Quad BeadChip 
in conjunction with Illumna’s iScan system allowed for more automation and organization, as the 
team was able to scan beadchips in just a few minutes (2011). The sequencing was found to be as 
accurate as other methods and the Illumina system extended the limit of detectability within 
mixtures of samples (2011). In summation, the Illumina system is ideal for dealing with complex 
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mixtures, and gives hope for the tracking of fugitives, determining the presence of an individual 
in a public place, and even understanding criminal groups.   
 
However, there are also some issues with using gene sequencing as part of forensics. For one 
thing, legislation has kept up with the increased gathering and analysis for the UK’s National 
DNA Database (ESRC, 2008). It is proposed that developments of technology must be met with 
respective developments in law, and this is exemplified in the reclassification of mouth swabs as 
non-intimate DNA collection (2008). Occurrences such as this verify the belief of some that the 
accuracy of DNA evidence makes exceptional legal procedures necessary.  As such, G8 countries have 
developed a protocol for the proper exchange of DNA evidence between nations, which includes 
weighing the rights of victims versus the rights of the accused, and considering that most 
innovations become practices through their application to specific cases, not merely by 
theorizing (2008). It is thought that ethical considerations may be overlooked in the future as the 
use of gene sequencing in forensics becomes more routine (2008).  
 
It is also difficult to build the trust of citizens about the retention of genetic evidence. In fact, 
some technologies could restrict access to genetic databases, with the main impacts being on 
privacy, autonomy, and social justice (ESRC, 2008). Any accessible privacy enhancing 
technologies would increase the autonomy of the system, but would not administer proper social 
justice because it would put those without access to technology or who at a disadvantage. 
However, non-accessible technologies reverse the issues described above. An additional issue is 
obtaining the trust of citizens in regards to the storage of genetic information in a database with 
genetic information from criminals (2008). This practice is done to simplify searches during 
criminal cases, but it can cause citizens to feel uncomfortable.  
 
Furthermore, the sequencing of children in cases of missing or kidnapped children also creates 
some dilemmas. These issues include gaining consent for minors, as described previously, and 
determining which parts of the genome should be disclosed to children and/or parents (ESRC, 
2008). In addition, as it becomes a common practice to obtain DNA samples from family 
members in order to track down criminals or gain insight into their genetic predispositions to 
criminal activity, issues such as people not wanting to be associated with criminal investigations 
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arise (2008). It also introduces another problem when a familial link is found that proves that 
criminality can run in a family, since the pool of possible suspects in a given case can then 
increase (2008).  
 
3.4 Medicine 
Advances in human genome sequencing have contributed to many aspects of the medical field 
including disease treatment, cancer research, personalized drug development, and vaccination. 
This has led to a new personalized approach in medicine that is specific to the patient and the 
disease in question.  
 
3.4.1 Medical Diagnosis, Treatment, and Cancer Research 
Generally speaking, personalized medicine involves the early prediction and detection of certain 
diseases, treatment and the development of drugs specific to the patient. Personalized medicine 
covers a wide range in medical process, from making predictions about an individual’s 
susceptibility to a certain disease, to the actual treatment (Duke Medicine, 2011).  
 
Prenatal testing is another area where the introduction of DNA sequencing has the potential to 
create large improvements for the patient and the clinician (Wright, et al., 2011). Currently, 
prenatal testing is done using chorionic villus sampling (CVS) and amniocentesis, which are both 
invasive ways to acquire a sample of the fetal DNA from inside the mother, and can involve risks 
such as miscarriage and tissue irritation. Research is being done on cell-free fetal DNA 
(cffDNA) that circulates in maternal blood plasma during pregnancy (2011). CffDNA is from the 
placental cells and thus could allow for prenatal testing that only requires a blood sample from 
the mother, an assay to separate the cffDNA from the maternal cells, and an appropriate gene 
sequencer. Unfortunately, much more research is required in this field before this future 
application can be materialized (2011).  
 
In addition, there are many mutants of the human immunodeficiency virus (HIV) and many have 
become resistant to commonly used drugs. It has become a practice to sequence the specific 
mutant of the virus in order to effectively treat the patient (Intelligent BioSystems, 2011). 
However, improvements in sequencing technologies are desired in order to be able to measure 
low population mutants (Intelligent BioSystems, 2011).   
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Furthermore, the advances in genome sequencing technologies, especially those regarding 
frequency of error, speed, and cost per genome have allowed gene sequencing to become a part 
of treating many cancer patients. Mutations that lead to cancer vary so highly across patients that 
some researchers believe that each patient’s genome needs to be sequenced in order to provide 
optimum cancer treatment (Intelligent BioSystems, 2011). The Cancer Genome Anatomy project 
has been launched by the National Cancer Institute to understand the varying mutations that lead 
to cancer (2011).  
 
3.4.2 Personalized Drug Development 
Personalized medicine can be defined as a special kind of medicine that allows for the 
customization of healthcare by using the genetic or related information of the patients in question 
(Duke Medicine, 2011). Pharmacogenomics is a field regarding the study of the way genetic 
variations affect how people respond to drugs (2011). As a result, pharmacogenomics and 
advances in DNA sequencing have built the foundation to the personalized medicine industry. 
 
To make personal drug development a realizable idea, several factors must be taken into account: 
 Genetic tests to prove the relationship between an individual’s genes and a given disease 
are needed. 
 It is necessary to successfully locate the genetic variant that causes the disease. 
 A drug needs to be developed that targets either the deficient phenotype of that gene, or 
provides direct gene therapy. 
 The response of an individual to the personalized drug must be analyzed for safety and 
effectivity. 
 
3.4.2.1 Current Development and Data  
Since the completion of the Human Genome Project by the U.S. Department of Energy and the 
National Institute of Health, the idea of developing medicine tailored to specific patients 
according to their genome has become feasible. One of the initial goals of the HGP was to 
associate particular genes to specific diseases (Gillham, 2011). Table 9 below compares genomes 
between humans and other organisms.   
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Table 10: Genome Sizes and Gene Density in Humans as Compared with Other Organisms  
(Data from Human Genome Project, 2003) 
Organism Estimated size 
(base pairs) 
Estimated 
gene number 
Average gene 
density 
Chromosome 
number 
Homo sapiens (human) 3.2 billion ~25,000 1 gene per 
100,000 bases 
46 
Mus musculus (mouse) 2.6 billion ~25,000 1 gene per 
100,000 bases 
40 
Drosophila 
melanogaster (fruit fly) 
137 million 13,000 1 gene per 
9,000 bases 
8 
Arabidopsis thallana 
(plant) 
100 million 25,000 1 gene per 
4,000 bases 
10 
Caenorhabditis elegans 
(roundworm) 
97 million 19,000 1 gene per 
5,000 bases 
12 
Saccharomyces 
cerevislae (yeast) 
12.1 million 6,000 1 gene per 
2,000 bases 
32 
  
 
Among the genomes researchers have sequenced, more than half of them have been found to be 
made up of repeating sequences. A large amount of research shows that most genetic diseases are 
caused by mutation in these regions (Gillham, 2011). In fact, in as early as 1993 scientists were 
able to successfully associate two copies of the APOE4 variant mutation with Alzheimer's 
disease (Angier, 1993). This study showed that people with this certain gene variation are eight 
times more likely to get Alzheimer's disease, and triggered the development of personalized 
drugs for the treatment of Alzheimer’s (1993).  
 
Currently scientists have developed several therapies, many of which have been used in practice. 
In 2006, 13 prominent examples of personalized drugs, treatments and diagnostic products were 
available (Personalized Medicine Coalition, 2011). By the end of 2011, this number increased to 
72, of which the average increasing rate is about 40.8% (2011). In addition, as of 2011, 33 
pharmacogenomic biomarkers are included on FDA-approved drug labels (Personalized 
Medicine Coalition, 2011). Most personalized drugs target a specific biomarker and the group of 
people who have the given biomarker can possibly benefit from using the drug (2011). 
Furthermore, the Personalized Medicine Coalition stated in their annual report that 30% of all 
personalized treatments in late clinical development, 50% of all treatments in early clinical 
development, and 60% of all treatments in preclinical development now rely on biomarker data 
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(2011). In the future, creating a database of biomarkers and their corresponding personalized 
drugs could significantly improve disease diagnosis and treatment in terms of speed and 
efficiency.  
 
Currently there are several incentives that encourage the development of personalized drugs . 
The first incentive is the decreasing cost of genome sequencing. Figure 19 is a graph indicating 
the decreasing sequencing cost per genome from Sept, 2001 to Sept, 2011, with data courtesy of 
the National Human Genome Research Institute.  
 
Figure 19: Cost per Genome from September 2001 to September 2011  
(Data from National Human Genome Research Institute, 2011) 
 
It is clear that the cost per genome is decreasing every year since 2001. However, the next 
generation sequencing technologies, which commercialized around 2007, have caused increased 
savings in recent years. 
 
The second incentive encouraging personalized drug development is that there is an increased 
amount of investment in this field. It has been reported that Siemens signed its first personalized 
medicine diagnostics deal with two drug production corporations, both of whose main goal is to 
develop genetic tests that will determine which patients will benefit from which therapies 
(Bloomberg, 2012). Furthermore, according to the Personalized Medicine Coalition, there has 
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been a 75% increase in the investment for personalized drugs over the last five years 
(Personalized Medicine Coalition, 2011). Most of the investment is towards genetic testing in 
order to associate certain mutant variants with diseases. Moreover, according to TriMark 
Publications in 2011, the market for molecular diagnostics, which includes tests related to that of 
personalized drugs, will more than double in the U.S. to $5.5 billion in 2016 (from its $2.5 
billion in 2010) (Bloomberg, 2012). 
 
3.4.2.3 Future Difficulties  
Unfortunately, there are many limitations to personalized drugs, including technical and social 
barriers. Currently, most of the personalized medicine available is not 100% guaranteed to work 
on the general population.  For example, research has shown that the drug Xalkori, developed by 
Pfizer Inc., might help patients who have non-small cell lung cancer (NSCLC) (Personalized 
Medicine Coalition, 2011). However, only about five percent of NSCLC patients can be 
effectively treated with Xalkori. These patients have tumors resultant of a mutated version of the 
anaplastic lymphoma kinase (ALK) gene (2011). Due to this low percentage of effectiveness, 
this drug is often the last choice in clinical settings (2011). 
 
Moreover, the progress in identifying important genetic variants is a bit slow due to the fact that 
there is usually little evidence showing that a common genetic variant will increase the risk of a 
given disease (Garber, 2009). An additional issue is that there has been little study to address the 
clinical utility of personalized medicine (2009). For example, it may be difficult for a doctor to 
convince his or her patients to spend the additional money for a genetic test in the hopes of 
receiving personalized medicine, especially if the doctor does not know how well the drug will 
work.  
 
Finally, many consumers are concerned that this area of pharmacology has not matured enough 
to be deemed completely safe and effective. In addition, personalized drugs require not only the 
patient’s sequencing information, but it also relies on the development of many other areas such 
as understanding the functions of certain regions of DNA and RNA.   
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3.4.3 Disease Prevention and Vaccination 
Risk assessment is the most widely-recognized application of current technologies. The tools that 
enable risk assessment and predication include health risk assessment, family history genome 
information and clinical decision support (Bauman, 2010). Some of the applications of genomic 
and personalized medicine include disease susceptibility, diagnosis and prognosis, 
pharmacogenomics and monitoring (2010). To put these applications into practice, genetic 
testing is sometimes integrated into clinical practice.  
 
Bacterial genome sequencing has enabled the development of effective vaccines. Two examples 
are vaccines for bacterial meningitis and for the many diseases pertaining to the Streptococcus 
strains (Tettelin and Feldblyum, 2009). Essentially, the knowledge of the DNA sequences 
allowed Tettelin and his colleague to find the resulting proteins, proteins functions, and the 
antigens of these bacteria that can be identified by the human immune system. The antigenicity 
(ability of structural and chemical structures on the bacterium to create an adaptive immune 
response), and pathogenicity (ability to cause disease) allows researchers to develop vaccines 
that can safely allow the creation of memory cells, which have the potential to reduce the 
symptoms and effects upon a second infection with the same strain due to the faster proliferation 
of antibodies by B lymphocytes (Bauman, 2010). Specifically, the vaccines developed for 
meningitis and streptococcus related diseases are made as “cocktails” that are a combination of 
denatured, attenuated, and/or modified antigens of these strains (2009).  
 
3.5 Advances in Genetic Research 
The advances made in second and third generation sequencing technologies paired with existing 
information on the human, bacterial, and viral genomes have enabled the identification of 
genotypic and phenotypic variances resultant of nucleotide deletions, insertions, inversions, 
frameshifts, and splicing (Tettelin and Feldblyum, 2009). Finding these differences and the 
relationships between genotype and phenotype will allow for further development of 
personalized medicine, better diagnosis, epidemiology, and disease prevention through more 
effective vaccines. For example, the 454 method was used to find and map more than 1000 
structural differences between two humans that were larger than 3000 bases, while using a 
standard human genome as the reference (2009). The 454 method was also used in combination 
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with Illumina sequencing technology to detect regulatory RNAs that play a role in gene 
expression (2009). 
 
Thus, molecular biology has been significantly impacted with the advances in genome 
sequencing technology because it is now easier to manipulate genes due to the knowledge of 
their sequences. Manipulating genes allows the discovery of gene function, regulation, and 
interaction, in addition to protein function, product, and interaction (2009). The following is an 
overview of various applications of second generation sequencing technologies in genetic 
researches. 
 
3.5.1 Mutation Discovery and Defining Variability Across Human Genomes 
Next generation sequencing technologies facilitate the discovery of mutations that determine 
phenotypes (Mardis, 2008). Previously, discovery of mutations were usually conducted with a 
direct focus on select regions of a genome of interest. However, the high speed of new 
sequencing technologies has made whole-genome search for mutations possible. Unfortunately, 
the short read length from the next generation methods, such as that of Helicos BioSciences, 
imposes certain limitations to this approach (2008).  
 
These advances in gene sequencing have also led to variability studies across human genomes. 
These studies are based on population levels. Currently, large numbers of human genomes can be 
sequenced to provide data for variability studies (Mardis, 2008). Rare alleles can be detected at 
the sequence level, while allowing for the capturing of large insertions and deletions at the 
genome scale (2008).  
 
3.5.2 Sequencing Clinical Isolates in Strain-to-Reference Comparisons 
For the study of pathogens, such as bacteria and viruses whose genomes mutate constantly, 
researchers would like to obtain rapid data about antibiotic susceptibility and resistance (Mardis, 
2008). The advances in sequencing technologies assist in this by providing complete genome 
sequences of different strains (2008). Since all of these sequencing methods obtain the fragment 
library from one single genome, variants in the clinical strains can be quickly identified. 
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3.5.3 Enabling Metagenomics 
Metagenomics refers to the study of DNA fragments directly taken from environmental 
microbial and viral populations, instead of a cultured lab setting (Mardis, 2008).  Samples are 
taken directly from the environment, so that the sequence reads are in rough proportion to the 
population frequency of each microbe, from which relative abundance can be estimated (2008). 
This concept is illustrated in Figure 20, which is also a graphic from the team’s final set of 
videos. A particular example is the study of billions of microbial species that humans live in 
symbiosis with, called the human microbiome. The third generation sequencing methods in 
particular demonstrate extremely high efficiency with short bacterial genomes because of the 
short read lengths produced by these sequencers, ideal for facilitating metagenomics studies. 
 
Figure 20: An Illustration of an Example of Metagenomic Studies 
 
3.5.4 Defining DNA–Protein Interactions and Regulatory Protein Binding 
DNA-protein interactions refer to the nuclear interactions between DNA and proteins that control 
DNA packaging into histones and/or the transcription of DNA into mRNA (Mardis, 2008). 
Previously these studies were only conducted on simple organisms with small genomes. 
However, with the assistance of second and third generation sequencing technologies researchers 
are able to understand the interaction processes in complex organisms with large genomes (2008). 
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Furthermore, the transcription of genes is regulated by protein binding sites on DNA. These 
binding sites are specific sequences recognized by regulatory proteins (Bauman, 2010). Using 
hybridization of fluorescently labeled DNA fragment enables genome-wide evaluation of 
binding sites (Mardis, 2008). The high throughput of next generation sequencers can provide 
enough data for all sites in the human genome within a single instrument run (2008).  
 
3.5.5 Exploring Chromatin Packaging and Noncoding RNAs 
Chromatin packaging is the packaging of genomic DNA into histones, which largely determines 
the transcription of genes (Bauman, 2010). Using next generation sequencing platforms, 
researchers are now able to better understand the histone binding locations genome-wide (Mardis, 
2008). These advances have also allowed for the discovery of noncoding RNAs and their 
locations, which include regulatory RNAs (2008). These types of RNA serve important functions 
in the cell cycle, in fact, mutations in noncoding RNAs are closely related to cancer and other 
human diseases (2008). 
 
3.6 Evolution 
Advances made in genome sequencing technologies have also affected the progress in the field 
of evolutionary biology.  The practice of comparative mapping is becoming more commonplace, 
and promises to have a huge impact in both healthcare and academic applications.  By comparing 
the complete genomes of livestock, it has been discovered that the genetic mutations responsible 
for muscular dystrophy and acute stress syndrome are the same ones that have an effect on 
malignant hypothermia in humans (O’Brien, et al., 1999).  Similar mapping of the X and Y 
chromosomes in marsupials have shed light on the origin and divergence of mammalian sex 
chromosomes (1999).  It is also interesting to note that as few as 13 translocation mutations 
separate the human genome from that of the cat family (1999).  It is expected that further 
comparative mapping will reveal whether the linkage associations that are depicted are 
accidental or whether they have been selected and retained due to dependence on those genes.  
Comparative mapping also creates the opportunity to highlight important genomic events such as 
epidemics, reproductive isolation, and survival in terms of their effect on forming new species 
(1999). 
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Second and third generation sequencing technologies that specifically identify SNP’s are also 
having a great effect in determining positive selection within ecosystems.  In humans, this data is 
being used to identify loci where particular alleles are being favored (Voight, et al., 2006). These 
alleles have not yet reached fixation, meaning that this information can be used to show which 
environmental and regional factors push alleles into fixation (2006).  One example is the study of 
alleles controlling chemosensory perception, gametogenesis, spermatogenesis, and fertilization.  
These have been identified as targets of selection in human-chimpanzee genetic divergence, and 
data suggests that these are relatively recent selections (2006). 
 
The field of phylogenetics, the study of the evolutionary development of organisms, relies 
heavily on a single assumption:  the species observed today can be symbolized as leaf nodes in a 
developmental tree in which ancestral species are internal nodes (Siepel, 2009).  As one travels 
along the branches of this tree, a genome changes through mutations until it reaches the genome 
of a modern-day species.  Factors such as topology and length of the branch can determine the 
ancestral sequence of a particular species (2009).  
 
The purpose of the statistical modeling and population considerations that are taken into account 
during the analysis of these trees is to attempt to reconstruct the ARG, or Ancestral 
Recombination Graph, for a species (2009).  To clarify, this graph is not a tree.  It begins with a 
single chromosome, and a tree can be extracted from it by taking a particular fork at any 
recombination event in the ARG (2009). These ARGs take into account population sizes, 
geographical barriers, and other causes of recombination that are possible at any evolutionary 
fork.  The main caveat in this method is that if a certain number of genealogies (at least 4) are 
present within the same species, the wrong “topology” may be favored, resulting in the wrong 
phylogeny for a species (2009).  This has been shown to happen rarely though, but more research 
is being done regarding the development of a more consistent estimator.  
 
In the end, this method shows promise for the prediction of evolutionary similarities between 
humans and different species of primates. However, substitutions may be over-counted, resulting 
in a bias towards the prediction of genes and negative/positive selection (Siepel, 2009). 
Unfortunately, the ARGs that link humans to primates on an evolutionary scale are difficult to 
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build based on current genomes alone (2009).  Developing a method to construct this to a high 
accuracy would open up a large realm of possibilities, but before this can be done, computational 
intractability and difficulties in modeling biological phenomena (such as the difference between 
species in recombination hot-spots) must be overcome (2009). The possibilities for genomic 
impact on evolutionary biology are huge, and it could be possible to further trace the phylogeny 
of a variety of organisms if these hurdles are overcome.  The implications of this research hold a 
particular impact on religion, science, and the way we view the environment.  
 
3.7 Agriculture 
Since the 1990s, sequencing technologies have been widely used in the agriculture industry. 
Using genetic information, scientists can identify genes that are responsible for specific 
phenotypic traits. Any beneficial genes (from plants or animals) discovered from these studies 
can be incorporated into our food sources if deemed safe (World of Genetics, 2006). Thus far 
scientists have sequenced the large majority of agricultural crops and have discovered a variety 
of important genes including those related to bacterial resistance, growth, and taste, which has 
led to the large amount of transgenic products currently available (2006).  
One of the aims of transgenic products is to increase resistance to pests, such as bacteria and 
insects. By 1998, there were approximately 175 registered bio-pesticide active ingredients and 
700 products (World of Genetics, 2006). In the case of cotton, the use of Bacillus thuringiensis 
in crops reduced the amount of chemical pesticides used by 450,000 kg in 1998 (2006). It can be 
seen that transgenic products featuring pest resistance have benefited people greatly by reducing 
costs and protecting the environment, thus making it extremely attractive to manufacturers and 
environmental protection agencies (2006). 
Another related that receives great interest is the development of transgenic products to provide 
additional nutrition value. It is thought that the problem of hunger and malnutrition in 
underdeveloped countries can be addressed by developing transgenic rice with additional 
nutritional content (Baggott, 2006). Fortunately, most of the technical problems to develop such 
crops have been solved. The idea and details of “golden rice” was first published in Science in 
2000 (Ye, 2000). This variant of rice is designed with a precursor of pro-vitamin A, and it is 
hoped that this will help prevent blindness and death due to a deficiency of vitamin A, which is 
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very common in developing countries (2000). Even though more varieties of transgenic rice are 
being developed and improved upon, “golden rice” raises some social concerns. In some cases, 
people have concerns regarding the safety of “golden rice” (Ingo, 2010).  
In 2006, the group of countries growing 97% of global transgenic crops was comprised of the 
United States (53% of crops), Argentina (17%), Brazil (11%), Canada (6%), India (4%), China 
(3%), Paraguay (2%) and South Africa (1%) (Cornejo, 2011). Figure 21 below displays a graph 
from the USDA (United States Department of Agriculture) indicating the adoption of transgenic 
crops in the USA from 1996 to 2011. This graph illustrates how transgenic crops now account for 
more than two-thirds of all crops grown in the United States, which is resultant of the fact that 
people in the U.S. generally accept the adoption of genetically engineered crops (2011). 
 
Figure 21: Adoption of Transgenic Crops in USA from 1996 to 2011  
(Cornejo, 2011) 
 
Transgenic foods can have many benefits including having additional nutritional value, and in 
some cases having better taste, which are both characteristics that have been found to be 
important to most consumers (2011).  
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 However, there are also a lot of concerns regarding transgenic foods, including allergy and 
safety risks, possible harm to other organisms in the environment, and ethical issues such as 
tampering with nature through genetic engineering across species (U.S Department of Energy, 
2008). In fact, a poll by Eurobarometer showed that the many European consumers find 
transgenic food dangerous (Baggott, 2006). Unfortunately, product safety is difficult to prove 
without long-term testing, so it is hoped that data in the years to come will enable consumers to 
make a more informed decision regarding the safety of ingesting transgenic crops. In addition, it 
seems that many countries are divided into two parties regarding the legislation of transgenic 
food (U.S. Department of Energy, 2008). While transgenic crops are adopted widely in countries 
such as the U.S, Argentina, Brazil and Canada, a lot of countries have banned transgenic food, 
such as France, Ireland and Russia (2008).  
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Chapter 4: Surveying WPI Students and Faculty 
 
Undergraduate students at Worcester Polytechnic Institute were surveyed in regards to their 
interest, opinion, and familiarity with recent genome sequencing technologies and their various 
impacts. Members of WPI faculty were surveyed in regards to their preferences for various 
aspects of our final deliverables as well as their interest in using our educational materials in 
their course(s). The information obtained from these two surveys enabled the team to make the 
educational materials more relevant and useful for the target demographic. Both of these studies 
were approved to be exempt from further review by the WPI Instructional Review Board (IRB).  
 
4.1 Creating and Implementing the Student Survey 
This study primarily involved a nomothetic approach to using survey methods in order to answer 
the following questions:  
1. Are students familiar with recent genome sequencing technologies and their impacts on 
government, medicine, research, and society?  
2. Which impacts of genome sequencing technologies are students most interested in learning 
more about?  
 
The team developed a list of questions to address these topics, revised them for clarity, and then 
proceeded to obtain an IRB exemption from further review. After obtaining this approval, the 
questions were inserted into an online form using SurveyMonkey, and distributed through email 
to the WPI moderated standing list for undergraduate students. All of these students had the 
option to participate and were told that their responses would be kept anonymous and 
confidential. A copy of the student survey can be found in Appendix I.  
 
Basic demographic information was obtained through the survey for the purposes of 
categorization and data analysis. The final draft of the student survey is included in Appendix I. 
No contact information was obtained from the student survey.  
 
The responders were grouped into categories based on their major (biology related majors vs. 
majors unrelated to biology) and the overall opinion, familiarity, and interest of each group was 
to be compared and then incorporated into creating a finished product that reflects the needs and 
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interests of the students most likely to encounter this video in their future courses. The survey is 
primarily quantitative and option-based in order to prevent the survey from being too time 
consuming and involved for participants. The quantitative statistics will allow for 
generalizations to be created in order to answer the two primary research questions. 
  
4.2 Results and Discussion of the Student Survey 
The team received 243 responses from WPI students in the first 24 hours since sending out the 
survey invitation. This response rate was higher than the team’s expectations. 
 
4.2.1 Respondent Demographics 
Generally speaking, the respondents to the student survey have a uniform class distribution, as 
was desired by the team. However, the mode of the data is the junior class. This may be resultant 
of the fact that all four team members are juniors as well, and thus their names on the survey 
email may have been recognized by their fellow 3
rd
 year classmates, moreso than students from 
other years. Yet, statistically speaking, there was no significant difference between the four 
groups (Freshmen, Sophomores, Juniors, and Seniors).  
 
Respondents were also asked of their major to see whether having a biology background 
impacted their responses. It was found that one-third of the students were biology related majors, 
such as Biology and Biotechnology (BB), and Biomedical Engineering (BME). The team was 
specifically interested in seeing whether students having a biology related educational 
background would exhibit more confidence in their understanding of DNA sequencing 
technologies, as well as whether they would show a higher interest in related topics such as the 
impacts on disease diagnosis, treatment, and prevention.  
 
It is also important to note that the respondents are restricted to WPI undergraduate students. As 
a result, this factor needs to be taken into account when drawing conclusions from this 
component of the study.                       
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4.2.2 Stated Familiarity and Interest Ratings on the Impacts of Genome Sequencing 
Technologies 
In addition to the overall interest shown regarding the various social and medical impacts of the 
advances in genome sequencing technologies, the team also wished to compare the amount of 
interest shown by different groups of undergraduate students. Generally, most respondents 
(62.3%) have at least some interest in learning more about the technical components of modern 
DNA sequencing methods.  This ratio is greater than what was expected due to the amount of 
prerequisite knowledge required in order to fully understand current sequencing methods.  This 
response shows that these WPI students are aware of that the technology behind genome 
sequencing is advancing at a fast rate and are thus genuinely interested in learning more about it.  
 
To check the specific interests shown in each area, the team made use of the crosstab feature of 
SurveyMonkey with one group made up of the biology related majors discussed previously, and 
the other group made up of those who have less of a biology related background.  Overall, the 
team expected the biology related group to be more familiar with how new genome sequencing 
technologies work. However, the team was also interested in learning how each of these groups 
view the various impacts of these technological advances.    
 
The respondents who were biology related majors, were found to have a higher confidence in 
their familiarity with the impacts relating to the medical field, such as personalized drug 
development and vaccination. Correspondingly, there were twice as many people expressing 
interests in these areas as opposed to the number of individuals expressing an interest in the 
impacts on the economy and legislation. It is worth noting that, though the economy is greatly 
affected by the advances in genome sequencing technologies, it received the lowest interest by 
both groups being analyzed. Some of these respondents discussed this with members of the team, 
and it was found that their low interest was resultant of their lack of awareness regarding how 
advances in genome sequencing affect the economy. This feedback indicates that one’s 
familiarity on a topic can affect their interest level in regards to learning more about the topic. As 
a result, the team decided that it was important to include in our educational material topics that 
received low familiarity and interest rates rather than purely having topics with high interest, 
with the hope that our introduction to the topic will stimulate further interest.  
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For the respondents who are not biology related majors, the median familiarity rate is only 1 (out 
of 5) for the impacts on ownership and privacy, legislation, economy and personalized medicine. 
This result indicates that they are not aware of the impacts of new DNA sequencing 
technologies, especially in areas other than the medical field. This group reported to have the 
highest familiarity on the impacts on genetics and evolutionary studies, which received an 
average familiarity rate of 2.38 (5 being the highest). 
 
In terms of the respondents’ interest, impacts on ownership and privacy, cancer research and 
genetic studies were the areas that received the highest amount of interest: 36%, 40% and 38% of 
all respondents respectively. In contrast, only 25 respondents reported to be interested in the 
impacts on the economy.   
 
In addition, two line charts were produced to compare the respondents’ confidence in their 
familiarity with the various impacts on genome sequencing technologies (Figure 22 below), and 
the percent of interest shown by biology related majors versus non-biology related majors 
(Figure 23 below). 
             
Figure 22: A Line Chart Comparing the Level of Familiarity on the Impacts of Sequencing 
Technologies of Biology Related Majors and Non-biology Related Majors 
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Figure 23: A Line Chart Comparing the Percent of Interest on the Impacts of Sequencing 
Technologies of Biology Related Majors and Non-biology Related Majors 
 
A T-Test was performed to see whether the differences between the responses of biology related 
majors versus non-biology related majors were statistically significant, and indeed there was a 
statistically great difference between the responses of these two groups. Respondents with a 
background in biology tended to state that they were more familiar and interested in the topics 
compared to those who did not have as large of a background in biology. The team’s goal was to 
depict the data using straight line segments and compare the shapes, so that an idea of whether 
this trend applies to a general population could be obtained.  
 
For the stated familiarity rate, the line segments are very similar in the shape. This allows the 
team to conclude that the average college student is at least somewhat familiar with how 
advances of sequencing technology has impacted the field medicine, while other areas such as 
legislation, and economy, are not as widely known. However, this similarity cannot be found 
with regards to the interest percentage except for the fact that both groups have the least interest 
in the impacts on the economy. Because of their background knowledge, and possibly due to 
their career goals, biology related majors displayed a higher level of interest in the areas related 
to medicine and biological research.   
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4.2.3 Student Responses to the Changes Brought By Advances in Sequencing Technologies 
 
The second part of the student survey was primarily focused on the reactions and opinions of the 
respondents in regards to the potential changes that could be brought upon by new sequencing 
technologies. Various situations were covered, such as the possibility of having individuals 
sequenced on a regular basis, and how people think about the potential social and legal issues 
that may arise, such as genetic discrimination. These survey questions can be found in Appendix 
I, and are noted as questions 7 through 15.  
 
Statistical analysis was completed for all of these questions but only a selection of these findings 
is included in the sections below. Specifically, chi-square tests were used to indicate whether 
there was an association between the responders’ personal views and the respondents’ 
background (biology related majors versus non-biology majors). The null hypothesis in each 
case assumes that these two variables are independent. Fisher exact tests were also used when the 
sample size was small. As the name indicates, the test calculates the exact probability instead of 
a simple approximation produced by chi-square test. As a result, it is useful when there is not a 
large enough sample to make accurate approximations from.  Fisher exact tests were performed 
using MATLAB code written by Giuseppe Cardillo. 
 
4.2.3.1 Issues Pertaining to Legislation, Privacy, and Disclosure 
Question 7 of the survey asked: A person’s genetic sequence can indicate whether they are 
predisposed to certain diseases. Do you think the government should prohibit health insurance 
companies from discriminating on the basis of one’s genetic makeup? 
 
The great majority (73.4%) of the student respondents stated that there should be legislation 
prohibiting health insurance companies from discriminating on the basis of genetic. In addition, 
88.9% of all respondents believe that a person’s DNA sequence should remain private. These 
responses show that students are concerned about the proper use and disclosure of genetic 
information. As discussed in section 3.2, the United States already has such legislation in place, 
but a worldwide consensus is still far away. About one-fourth of survey respondents do not 
support having such legislation. 
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When comparing the responses from biology related majors versus non-biology related majors, 
the chi-square value χs
2
 was found to be 1.31. The corresponding P value is 0.2524, which is 
greater than 0.2.  As a result, the null hypothesis, which assumes an individual’s major does not 
affect his or her choice, cannot be rejected.  Based on this result, the team concludes that the 
majors of the respondents did not have a great influence on how they view genetic discrimination 
by insurance companies. Generally three-fourths of all respondents support the idea of 
prohibiting genetic discrimination by insurance companies. 
 
The responses from different class years were also statistically compared. The chi-square value 
χs
2
 was calculated to be 5.86. The corresponding P value is 0.1186, which is less than 0.2. As a 
result, the team rejected the null hypothesis that an individual’s class does not affect his or her 
choice. However, based on these results, it can be said that there exists an association between 
the class year of respondents and their view on genetic discrimination. For example, more 3
rd
 
year students than any other class responded that they support the idea of prohibiting insurance 
companies from discriminating based on one’s genetic makeup. This response was followed by 
4
th
 year students. It is interesting that upperclassmen seemed to be more concerned about genetic 
discrimination than first and second year students.  
 
4.2.3.2 Issues Pertaining to the Economy 
Question 9 of the survey asked: The Human Genome Project was the second most expensive 
scientific program in human history. Do you think further government investment into this field 
will have a positive effect on United States economy?  
 
It was found that the respondents were divided in regards to their opinion about whether 
advances in genome sequencing will boost the economy. Approximately half of them (46.6%) 
believe it can improve the economy, while the other half (45.1%) hold the opinion that the 
investment can have positive effect but is not worth the investment. 8.3% stated that they were 
not sure about their opinion. Since these respondents reported to have a low level of familiarity 
with how DNA sequencing technologies affect the economy (lowest amount of reported 
familiarity and lowest percent of interest, as seen in Figures 22 and 23 respectively), it would be 
very interesting to conduct a survey after students watch the video in order to gather data on how 
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they review the relationship between advances in sequencing technologies and the economy after 
learning more about the topic.  
 
It is important to note that more than half of all respondents stated that they were not sure or that 
they do not see the investment having a positive effect on the U.S. economy. The responses from 
biology related majors versus non-biology related majors were compared, and the chi-square 
value χs
2
 was calculated to be 2.82. The corresponding P value is 0.2411, which is greater than 
0.2. As a result, the null hypothesis, which assumes a person’s major does not affect his or her 
choice, cannot be rejected.  Thus, the team concludes that the majors of the respondents did not 
have a significant amount of influence on how they view this topic. However, the survey results 
show that respondents with more of a background in biology hold a more positive view of 
genetic technology.  
 
Responses from different class years were statistically compared as well even though there was a 
smaller sample size. As a result, a Fisher exact test was chosen to be done. Using the Monte 
Carlo Method, the P value was calculated to be 0.5888, which is quite large. This indicates that 
there is almost no association between the respondents’ class year and their view on how 
sequencing technology affects the economy. About one-tenth of all respondents believe that 
there is no positive outcome on the economy compared to the amount invested. Based on these 
results and the research the team conducted on the impacts on the economy, it can be deduced 
that many people are not aware of the positive impacts sequencing technologies have on our 
economy.  
 
4.2.3.3 Opinions Regarding the Impacts on Medicine and Biologic Research 
62.5% of respondents stated that they believed that new sequencing technologies will make it 
possible to prevent and cure cancer. At the same time, about 28.8% of the respondents said they 
were not sure if the technologies would be able to enable this. 8.7% believed that these 
technologies would not lead to the possibility of preventing and curing cancer. Currently, cancer 
is difficult to both prevent and cure, so these answers are not outliers at all.  
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In addition, 71.5% of respondents stated that further research into sequencing technologies will 
change the diagnosis and treatment of disease dramatically. However, there were still 
respondents who were not sure (19.8%) or thought that the diagnosis and treatment of disease 
would not change dramatically (8.7%). 
 
Furthermore, 83.7% of respondents stated that they believe advances in sequencing technologies 
would bring further insights on the study of genetics and evolution. Compared to the previous 
two questions in this series, respondents seemed to have a more positive outlook regarding the 
potential of genetic and evolutionary studies. Given the many of the current genome sequencing 
technologies is being used to further the study of genetics and evolution, this feedback from the 
respondents was reasonable. 
 
Question 10 of the survey asked: Personalized drug development is made possible by recent 
genome technologies. These drugs are made on the basis of one’s genetic makeup. It is 
potentially more effective, but it can cost more and has certain safety concerns. If you were given 
the option of using a personalized drug for a severe disease, would you use it? 
 
Approximately two-thirds of the respondents expressed that they would be willing to use a 
personalized drug for a severe disease, while one-third of the respondents were not sure about 
using this treatment. It is understandable that the high cost and safety concerns may make them 
people rethink the prospect of using personalized drugs.  
 
The responses from biology related majors and non-biology related majors were compared once 
again. For this result there was a smaller sample size, and thus a Fisher exact test was used. The 
Monte Carlo Method was used and the P value was calculated to be 0.5888, which is quite large. 
This indicates there is almost no association between respondents’ background and their 
willingness to use the personalized drug. This may be resultant of the fact that personalized 
medicine is still a relatively new area that people still need more information on before they can 
make an informed decision. 
 
79 
 
Again, responses from different class years were statistically compared using the Monte Carlo 
Method. Here the expected frequency for people answering no is so small that fisher exact test 
has to be used again. The P value was calculated to be 0.0717, which also indicates that there is 
no significant association between respondents’ class year and their willingness to use 
personalized drugs. Generally there are very few respondents who directly state that they would 
refuse personalized medicine, but one-third of them are still not sure for due to considerations 
regarding cost, safety, and effectiveness.  
 
4.2.3.4 Opinions Regarding Volunteer Participation in Genome Related Research 
Question 15 of the survey asked: Imagine that a large genome research project is being carried 
out on a population basis around the globe, and it is recruiting volunteers to have their genome 
sequenced as data for the research. The volunteers are anonymous and only demographical 
information is recorded. Would you volunteer to participate in the study? 
 
Nearly three quarters of the respondents were willing to participate in a worldwide genome 
research project by having their genome sequenced with only demographical information 
recorded. For this question there was no option regarding unsure responders, and thus, the other 
quarter of respondents reported that they would not be willing to participate in such a study. 
Based on this response, in theory, if such a research project is carried out in the future, there 
would be a sufficient number of volunteers in order to collect sound data.  
 
4.3 Creating and Implementing the Faculty Survey 
The second component of this study aimed to find whether faculty members teaching courses in 
biology, biomedical engineering, bioethics, government, and biostatistics would be interested in 
using our educational materials in their courses. In addition, the team hoped to use the results 
from the survey to envision how our potential educational materials would be presented to 
students and whether the video should be full length or broken into shorter segments based on 
topic. The overall opinion and interest of the participants were analyzed and then incorporated 
into the creation of the educational materials. Similar to the student survey, the faculty survey 
was made primarily option based in order to prevent the survey from being too time consuming 
and involved. 
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Similar to the methods involved in creating the student survey, the team developed a list of 
questions, revised them for clarity, and then proceeded to obtain an IRB exemption from further 
review. After obtaining this review, the questions were inserted into an online form using 
SurveyMonkey, and distributed through email to the moderated standing list for WPI faculty. 
All of these faculty members had the option to participate and were told that their responses 
would be kept anonymous and confidential.  
 
Demographic information regarding the courses they teach was obtained through the survey for 
the purposes of categorization and data analysis. The final draft of the faculty survey is included 
in Appendix II. Unlike the student survey, faculty participants had the option to provide their 
email address if they were interested in previewing our educational materials for potential use in 
their courses, and/or if they were interested in providing suggestions to the team. However the 
email field was kept separate from the other response fields and as a result did not allow for 
identification of the participants based on their answers to the other questions.  
 
4.4 Results and Analysis of the Faculty Survey 
The number of responses obtained from the faculty survey was much lower than the student 
survey. Only 8 responses were collected from WPI faculty, and these respondents comprised the 
following departments: Biology and Biotechnology, Mathematics, Humanities and Arts, 
Computer Science, and Social Science and Policy Studies.  
 
All but one participant showed at least some interest in showing the team’s educational video to 
their class. In addition, all but one participant preferred the video to be broken up into segments 
based on topic rather than being a full length 40 minute video. This preference is probably 
resultant of the fact that class time is very limited, and as a result, having the video available 
online where students can be directed to watch it as a homework or extra credit assignment is 
much more convenient and time efficient. The team also determined that breaking the video up 
into segments allowed the video to be applicable to a larger range of courses, as course 
instructors could select the segments that are most relevant to their course for their students to 
view. For example, a professor of the social sciences department may select the segments 
pertaining to ownership and genome privacy, legislation, and economics for his/her course, while 
81 
 
a professor of biotechnology courses may select the segments pertaining to the genome 
sequencing technologies themselves as well as their various impacts on the medical field.  
 
Furthermore, the team was interested to find that approximately half of the responders stated that 
they would show the video and/or specific video segments in class, while the other half stated 
that they preferred the videos be available online for students to view on their own. The team 
would have like to have more respondents in this case in order to have a statistically preferred 
viewing medium. However, the team addressed this issue by posting the final set of videos on 
YouTube so that course instructors could decide for themselves whether they wanted to show the 
video and/or segments in class or direct students to view it on their own. Creating YouTube links 
also enables instructors to link to it through the course site (myWPI in the case of this 
institution). Likewise to the question pertaining to the preferred viewing medium, approximately 
half of the respondents preferred to have supplemental written assignments while the other half 
did not. The team addressed this issue by creating a short assignment for each video segment and 
making it available to those who are interested in using it.  
 
The impacts made by sequencing technologies on disease treatment as well as genetic and 
evolutionary studies received the highest amount of interest from the faculty. It is also important 
to note that the faculty members were interested in the impacts sequencing technologies have on 
the economy, since this received the lowest interest from the student respondents.  
 
As a follow-up to the survey, one faculty member suggested that the team look into researching 
the social and government implications of genome sequencing technologies in other countries as 
well. It was further suggested that this information could initiate a classroom debate where 
students research the views of various countries and participate in a model UN type of 
discussion. The team responded to this suggestion and this information was incorporated into 
both the educational video through the Impacts on Worldwide Legislation segment, as well as 
the supplemental assignment for that segment, which includes debate topics.  
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Chapter 5: Developing Educational Materials  
The following sections describe the methodology of developing the final set of online videos and 
their supplemental assignments. It is hoped that using these materials in conjunction will allow 
people to learn about this subject as well as demonstrate their understanding to an instructor.  
 
5.1 Creating the Preview Video and Obtaining Feedback 
The primary component of the educational materials developed was the set of online videos. 
Most of the images and text used in these videos were created by the team members, and all of 
the video animation, script writing, and narration was also done by the team. Adobe Photoshop 
CS 5.1 was used for image creation and adjustment, Adobe Flash CS 5.5 was used for 2-
dimmensional animation, and Adobe Premiere Pro CS 5.5 was used to compile the animation 
sequences, music, narration, and subtitles together. Autodesk Maya 2012 was used to create a 
model that was later used as an image in many segments of the video. In addition, Camtasia 
Studio 7.1.1 was used to record the narration as well as to create the tutorial in the Algorithms to 
Align Sequences video segment. Along with the creation of the visual components, a script was 
written for each segment of the video and then recorded. All together, approximately 35 minutes 
of film was made using this workflow. The sources for any borrowed images or music clips were 
credited at the end of each video.  
 
In order to obtain suggestions for improvement during the video creation process, the team 
compiled a preview video that contained the following segments: First Generation Sequencing 
Technology, Second Generation Sequencing Technologies, Third Generation Sequencing 
Technologies, Impacts on the Economy, and Impacts on Personalized Medicine. These were in a 
preliminary form and thus did not yet have an introduction and credit sequence.  
 
WPI professors who expressed an interest in previewing our material were provided with these 
video segments along with a feedback form. This form asked for their rating on the informational 
content, animations, use of subtitles, and the music, while asking how willing they would be to 
show videos similar to their students in the future. A copy of this feedback form can be found in 
Appendix III.  
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Overall, the response was very high, as the professors stated that the preview segments were well 
done, and that the videos provided a brief but engaging overview on each of the topics. In fact, 
the team was invited to a luncheon by the Bioinformatics and Computational Biology (BCB) 
program to share some of the segments from the preview video to students in the WPI BCB 
program, who also found our work thought-provoking.  
 
5.2 Creating and Posting the Final Set of Videos 
The group continued to create videos of individual segments, such as Impacts on Disease 
Prevention and Treatment, and Impacts on Forensics. A credit sequence was created and added 
to each video as well. These 12 segments were then combined into three broad sections: 1
st
, 2
nd
, 
and 3
rd
 Generation Genome Sequencing Technologies, Social Impacts of Genome Sequencing 
Technologies, and Impacts of Genome Sequencing Technologies Related to Medicine and 
Biological Research. A general introduction segment was created as well.  
 
At this point, the videos were uploaded onto YouTube as the 12 individual segments as well as 
the three compiled segments, and a playlist was created for each form (the 12 segments, and the 
three part video). The team chose YouTube as the medium of choice because it allows for 
maximum exposure and thus will enable a very large audience to benefit from the information. It 
was also requested of the team to send the final set of videos to the WPI Bioinformatics and 
Computational Biology program for possible future use.  
 
In both cases, viewers are able to contact the team via email for a copy of the related 
assignments, in the case they are interested in using it in their classroom. Viewers are also 
encouraged to leaved constructive comments for improvement (once approved). The description 
field of each video contains a message pertaining to this.  
 
All of our videos can be accessed through the team’s YouTube Channel: 
http://www.youtube.com/user/ImGenTechWPI/videos. The final list of videos and their run time 
is as follows:  
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3 Part Video 
 1st, 2nd, and 3rd Generation Genome Sequencing Technologies (14:40) 
 Social Impacts of Genome Sequencing Technologies (11:16) 
 Genome Sequencing Technologies: Impacts on Medicine and Biological Research (7:47) 
Individual Segments 
 Impacts of Genome Sequencing Technologies: Introduction (1:38) 
 1st Generation Genome Sequencing: The Sanger Method (2:33) 
 2nd Generation Sequencing Technologies: Roche 454, Illumina, and Applied Biosystems 
(4:40) 
 3rd Generation Sequencing Technologies: Helicos tSMS and Pacific SMRT Technology 
(3:24) 
 Using Algorithms to Align Sequences (4:20) 
 Genome Sequencing Technologies: Impacts on Ownership and Privacy (2:10) 
 Genome Sequencing Technologies: Impacts on Worldwide Legislation (4:24) 
 Genome Sequencing Technologies: Impacts on the Economy (2:27) 
 Genome Sequencing Technologies: Impacts on Forensics (2:32) 
 Genome Sequencing Technologies: Impacts on Disease Prevention and Treatment (1:43) 
 Genome Sequencing Technologies: Impacts on Personalized Medicine (2:27) 
 
5.3 Creating Supplemental Assignments 
Partly in response to the faculty survey and suggestions, the team also developed a short 
assignment for each segment of the final video. The final set of assignments is included in 
Appendix IV. Since users are able to view the videos by individual segments in addition to the 
three part video, questions were developed for each segment of the video. The answers to most 
of these questions are contained in our video, while others initiate students to conduct further 
research on a specific area. These assignments will be made available to instructors upon request. 
The description field underneath each video in the playlist will direct instructors to email 
imgentech12@gmail.com if they wish to access the assignments related to the video.   
 
Most of the questions are either identification or open response type questions to test a student’s 
understanding of the material presented in the video. A few questions ask the student to go 
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beyond the material in the video by conducting additional research. It is hoped that these 
research based questions will instigate students to learn more about this field, as the advances in 
these technologies may very well impact their lives at some point. In addition, due to the 
suggestion made in regards to creating debate topics for the classroom, the assignment for the 
Impacts on Worldwide Legislation segment includes three debate topics where students can 
conduct further research and represent different countries around the world in a discussion 
similar to the set up of a model United Nations.  
 
5.4 Future Usage of the Set of Videos and Supplemental Assignments in the 
Classroom 
Furthermore, some of the faculty who provided input to the team during the creation and 
development process have expressed tentative interest in using our educational materials in their 
related courses in the future. This includes faculty members from the Bioinformatics and 
Computational Biology Department (BCB), Biology and Biotechnology Department (BB), and 
Social Science and Policy Studies Department (SSPS).  
 
Fortunately, since all four members of the team will remain at WPI for at least one more year, 
the team members will be able to assist in the transition and implementation process if 
applicable, and hopefully view the positive results from adding our materials to WPI courses. 
After graduating from WPI, the group plans on having at least one member of the team 
periodically monitor the team email address and the YouTube account in order to respond to any 
requests made my educators for more information.  
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Chapter 6: Conclusions and Recommendations 
 
This chapter begins with a collection of the conclusions from the whole team. In addition, 
recommendations for future modifications and extensions of the project itself are also included.  
  
6.1 The Team’s Conclusions on the Impacts of Genome Sequencing Technologies 
Through the process of researching and creating educational material for all the topics the team 
covered, many different aspects of the impacts gene sequencing has on society were uncovered.  
As such, it is the team’s conclusion that each successive generation of gene sequencers has a 
significant impact on society.  Technologies are becoming more streamlined and efficient, and 
more applications for them are being discovered daily.  The genome industry has a positive 
effect on the United States’ economy and has the potential to improve our quality of life through 
a variety of avenues such as personalized medicine, forensic applications, and genetic research.  
However, more legislation from nations around the world is necessary in order to preserve 
human rights and ensure that the information obtained from gene sequencing is used for good 
rather than for personal gain.  The team concludes that the world is close to a time when gene 
sequencing will be fast, affordable, and widely used for the improvement of our lives. 
 
6.2 Future Recommendations 
Based on the team’s experiences during the course of the project, we propose the following 
recommendations for those who wish to either conduct a project very similar to this and/or wish 
to continue this project: 
 Encourage faculty members to respond to surveys and/or shorten the email and survey so 
that they are more likely to respond.  
 Clarify between when survey respondents should answer with only one response or 
multiple. 
 Create storyboards for each animation sequence as a team rather than solely by the 
animator in order to facilitate the process of combining images, voice, music, and 
animation all created by separate individuals. 
 Use a software program such as Autodesk Maya to create three dimensional models and 
animations in order to add a more professional look to the final videos.  
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 Create a focus group of students to assess the understanding of various impacts of 
genome sequencing technologies before and after having individuals watch the final set 
of videos. Then analyze this data to determine whether the video proves to be effective in 
its goal to educate others about this subject. 
 Consider the creation of other types of educational materials to communicate the same 
information, such as an interactive website, a computer game, or a mobile application.  
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Appendix I: Student Survey 
 
IQP: Impacts of Genome Sequencing Technologies 
 
1. What is you class? 
□Freshman   □Sophomore  □Junior  □Senior  □Graduate student 
2. What is your major? 
□BME  □BB  □Other Biology related majors  
□ Statistics  □Other Engineering  □Other Sciences  □Other majors 
3. How many courses in Biology, BME, Biostatistics and/or Bioethics have you taken? 
□0-2  □3-5  □5-10  □10-15 □15 or more 
4.  Do you have any background knowledge on the technological aspects of modern DNA 
sequencing methods? (eg. How a strand of DNA is sequenced) 
  □Yes  □No 
5.  Are you interested in learning the technological aspects of the modern DNA sequencing 
methods?  
□Highly interested  □ Some interest  □ Little interest 
□Not interested  
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6.  Are you familiar with the following aspects in which potential impact brought by the new 
genome technologies would occur? In addition, are you interested in learning more about 
these aspects? 
(Gradient: 1 for not familiar at all, 5 for very familiar, Check the aspects you are interested 
in learning about) 
Impacts 1 2 3 4 5 Yes, I am 
Interested 
Social impacts - - - - - - 
Ownership, Privacy and Disclosure of personal 
genomes 
      
Legislation (Genetic Information 
Nondiscrimination Act, GINA) 
      
Economy and Industry       
Human Medicine - - - - - - 
Personalized Drug Development       
Vaccination       
Cancer Research       
Disease Treatment       
Disease Diagnosis       
Scientific Research - - - - - - 
Genetics and Evolution       
Agriculture       
 
Questions 7-15 are based on the aspects of the impacts mentioned above. 
7. A person’s genetic sequence can indicate whether they are predisposed to certain diseases. 
Do you think the government should prohibit health insurance companies from 
discriminating on the basis of one’s genetic makeup? 
  □Yes  □No 
8.   Do you think that a person’s DNA sequence should remain private? 
   □Yes  □No 
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9.  The Human Genome Project was the second most expensive scientific program in human 
history. Do you think further government investment into this field will have a positive 
effect on United State’s economy? 
 □Yes  □No   
□It could have positive effect, but the investment would be more useful if it was allotted 
towards other research. 
10.  Personalized drug development is made possible by recent genome technologies. These 
drugs are made on the basis of one’s genetic makeup. It is potentially more effective, but it 
can cost more and has certain safety concerns. 
If you were given the option of using a personalized drug for a severe disease, would you 
use it? 
□Yes  □No  □Not sure 
11. The occurrence of certain types of cancer is closely related with mutations in a person’s 
genome. Do you believe that new genome technologies will enable researchers to find ways 
to prevent and cure cancer in the next decade? 
□Yes  □No  □Not sure 
12.  Do you believe that further genome research will dramatically change diagnosis and 
treatment of disease in the next decade? 
□Yes  □No  □Not sure 
13.  Do you think new genome sequencing technologies would bring insights on studies of 
genetics and evolution? 
□Yes  □No  □Not sure 
14.  If you could get your entire genome sequenced for under $100 someday, would you choose 
to be sequenced? 
 □Yes  □No   
15.  Imagine that a large genome research project is being carried out on a population basis 
around the globe, and it is recruiting volunteers to have their genome sequenced as data for 
the research. The volunteers are anonymous and only demographical information is 
recorded. Would you volunteer to participate in the study? 
 □Yes  □No   
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 Appendix II: Faculty Survey 
 
IQP: Impacts of Genome Sequencing Technologies 
 
1. What department are you in? 
        ______________________ 
2. What is your concentration/specialization? 
     ______________________ 
3. What courses do you teach at WPI? 
Undergraduate_______________________________ 
Graduate____________________________________ 
 
4. Would you be interested in showing a video to your class about recent genome sequencing 
technologies and their impacts on government, industry, research, medicine, and society? 
□Highly interested  □Some interest  □little interest   
□Not interested 
5.  If you are interested in showing such a video, would you prefer a full-length (40-50 min) 
video or videos broken into segments? 
 □Full length  □Segments 
6.  Would you prefer to show students the video in class, post it on myWPI or give students a 
YouTube link? 
 □In class  □myWPI  □YouTube link 
□Other forms, please explain _____________ 
7.  Would you prefer to have questions relating to the contents of the video and answer keys as 
assignments/extra credit for your students? 
 □Yes  □No 
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8.  Are you familiar with the following aspects in which potential impact brought by the new 
genome sequencing technologies would occur? In addition, are you interested in learning 
and/or teaching more about these aspects? 
(Gradient: 1 for not familiar at all, 5 for very familiar, Check the aspects you are interested 
in learning about) 
 Impacts 1 2 3 4 5 Yes, I am 
Interested 
Social impacts - - - - - - 
Ownership, Privacy and Disclosure of personal 
genomes 
      
Legislation (Genetic Information 
Nondiscrimination Act, GINA) 
      
Economy and Industry       
Human Medicine - - - - - - 
Personalized Drug Development       
Vaccination       
Cancer Research       
Disease Treatment       
Disease Diagnosis       
Scientific Research - - - - - - 
Genetics and Evolution       
Agriculture       
 
9.  (Optional) If you are interested in the video and would like to see a preview of it, please 
leave your email address so that we may contact you. _______________________ 
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Appendix III: Feedback Form for Video Preview 
 
Name: 
 
1)  How thorough did you find the information covered in the video? 
Not informative  1 2 3 4 5 Very informative 
 
2)  Please rate the quality of the animations 
Not good at all  1 2 3 4 5 Very good 
 
3) Did you find the subtitles helpful? 
Not helpful   1 2 3 4 5 Very helpful 
 
4)  Did you find the music distracting? 
Very distracting  1 2 3 4 5 Not at all distracting 
 
5)  At this stage, how willing would you be to show/post a video similar to this to your class? 
Not at all   1 2 3 4 5 Extremely willing 
 
Additional Comments: 
Please email the group with the feedback in the body of the email, or attached to the email. 
Alternatively, you may print this out and give it to Professor Zheyang Wu. We appreciate your 
time and thank you for your feedback! 
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Appendix IV: Supplemental Assignments 
 
Based on faculty interest, the team has developed supplemental assignments to support the 
content of our videos. The answers to most of these questions are contained in our video, while 
others initiate students to conduct further research on a specific area. These questions allow 
students to display their understanding of the content to the professor using it in their course.  
Introduction 
 
1. Who developed the chain termination sequencing method? 
2. Name some of the companies who have developed second and third generation 
sequencing technologies.  
3. How do you think these advanced genome sequencers will affect our society? 
 
1
st
, 2
nd
, and 3
rd
 Generation Sequencing Technologies 
 
1. Based on the video segment about the Sanger Method, summarize how the chain 
termination method of sequencing works. 
2. How did each of the second generation technologies mentioned in the video improve 
upon the Sanger Method?  
3. What are the differences between the technologies developed by Roche, Illumina, and 
Applied Biosystems? 
4. What are the similarities and differences between Helicos BioSciences sequencing 
technology and Pacific Biosciences sequencing technology? 
 
Using Algorithms to Align Sequences 
 
1. Why is developing algorithms important in modern biological data processing?  
2. Name two algorithms widely used in computational biology.  
3. There are many variants of BLAST; find information about each of them and explain 
how they are different from each other.  
 
Social Impacts Regarding Genome Related Ownership, Privacy, and Disclosure 
 
1. What are some of the issues with the transfer of genetic information between research 
institutions and between countries? 
2. Imagine that you wish to have a gene therapist develop a pedigree and provide the 
chances that one of your children will be born with muscular dystrophy. What are some 
of the issues that will have to be addressed regarding the sequencing of the members of 
your family? How would you address the question of sequencing a deceased family 
member and their rights? 
 
Impacts on Worldwide Legislation 
 
1. Which country was first to create legislation against genetic discrimination? What is the 
full name of this act? 
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2. What are some of the factors that affect how countries deal with genetic discrimination??  
3. Debate Topics 
It is suggested that students research the views of different countries and represent them 
in a model UN type of debate to address the following questions.  
 “Should we use human genome sequencing to enable improved disease diagnosis, 
treatment, and prevention?”  
 “Should we ban or limit the use of genetic testing in order to prevent legal cases 
of genetic discrimination?” 
 “Should there be a government agency or committee to oversee occurrences of 
genetic discrimination?” 
 
Impacts on the Economy 
 
1. Which genomic related area(s) currently offers the most job opportunities?  
2. The Human Genome Project is one of the most invested projects by the U.S. government. 
What year did this project start? What year did the HGP end? 
3. What are the results and implications for the funding of genetic research? 
 
Impacts on Forensics 
 
1. What are STRs and why are they involved in forensic studies? 
2. What are some of the social and legal issues involved in sequencing individuals for 
forensic evidence? 
 
Impacts on Disease Diagnosis, Treatment, and Prevention 
 
1. For the most part, the sequencing of what organism(s) led to the development of vaccines? 
2. Explain what a pedigree is, and how it allows someone to know the probability that a 
patient will develop a given disease? 
3. What is the specific characteristic of HIV that makes it difficult to treat, and how have 
the advances in genome sequencing technology improved the treatment of AIDS patients? 
 
Impacts on Personalized Medicine 
 
1. Find information about an FDA approved personalized drug and explain how it works. 
(Please include what this drug targets and how it helps treat a given disease.)  
2. Do you support the investing of large amounts of money into genetic testing to develop 
personalized medicine? State reasons for your argument.  
Impacts on Genetics and Evolutionary Studies 
 
1. Describe metagenomics. 
2. Describe comparative genomics and provide two examples of applications of this.  
           
